CA2787661C - Vaccine vectors and methods of enhancing immune responses - Google Patents
Vaccine vectors and methods of enhancing immune responses Download PDFInfo
- Publication number
- CA2787661C CA2787661C CA2787661A CA2787661A CA2787661C CA 2787661 C CA2787661 C CA 2787661C CA 2787661 A CA2787661 A CA 2787661A CA 2787661 A CA2787661 A CA 2787661A CA 2787661 C CA2787661 C CA 2787661C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- vaccine vector
- immunogenic fragment
- antigenic polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims abstract description 203
- 229960005486 vaccine Drugs 0.000 title claims abstract description 183
- 230000028993 immune response Effects 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title abstract description 29
- 230000002708 enhancing effect Effects 0.000 title abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 259
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 256
- 229920001184 polypeptide Polymers 0.000 claims abstract description 253
- 230000000890 antigenic effect Effects 0.000 claims abstract description 101
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 239000003937 drug carrier Substances 0.000 claims abstract description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 62
- 239000002157 polynucleotide Substances 0.000 claims description 62
- 102000040430 polynucleotide Human genes 0.000 claims description 62
- 239000012634 fragment Substances 0.000 claims description 55
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 51
- 230000002163 immunogen Effects 0.000 claims description 44
- 206010022000 influenza Diseases 0.000 claims description 39
- 108091005703 transmembrane proteins Proteins 0.000 claims description 27
- 102000035160 transmembrane proteins Human genes 0.000 claims description 27
- 230000003308 immunostimulating effect Effects 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 21
- 208000037797 influenza A Diseases 0.000 claims description 19
- 230000005875 antibody response Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 101150101706 cotB gene Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108700010013 HMGB1 Proteins 0.000 claims description 5
- 102000055207 HMGB1 Human genes 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000588807 Bordetella Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 4
- 101150021904 HMGB1 gene Proteins 0.000 claims 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 102000000849 HMGB Proteins Human genes 0.000 abstract description 5
- 108010001860 HMGB Proteins Proteins 0.000 abstract description 5
- 230000004044 response Effects 0.000 abstract description 5
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 64
- 102100037907 High mobility group protein B1 Human genes 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 31
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 30
- 241000287828 Gallus gallus Species 0.000 description 28
- 235000013330 chicken meat Nutrition 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 26
- 238000011282 treatment Methods 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 101710154606 Hemagglutinin Proteins 0.000 description 15
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 15
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 15
- 101710176177 Protein A56 Proteins 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 239000000185 hemagglutinin Substances 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 235000014469 Bacillus subtilis Nutrition 0.000 description 14
- 244000063299 Bacillus subtilis Species 0.000 description 14
- 241000271566 Aves Species 0.000 description 13
- 102000007999 Nuclear Proteins Human genes 0.000 description 12
- 108010089610 Nuclear Proteins Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000016784 immunoglobulin production Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 230000004936 stimulating effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 238000003305 oral gavage Methods 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 101150013553 CD40 gene Proteins 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 206010064097 avian influenza Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 208000002979 Influenza in Birds Diseases 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 244000144977 poultry Species 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 229960001212 bacterial vaccine Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101100389345 Bacillus subtilis (strain 168) ndoA gene Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000053637 human HMGB1 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 101150012518 lamB gene Proteins 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 101150048352 mazF gene Proteins 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- SGWFGVQCRDTUQN-UHFFFAOYSA-N (2-prop-2-ynoyloxy-3-prop-2-ynoylsulfanylpropyl) prop-2-ynoate Chemical compound C#CC(=O)OCC(OC(=O)C#C)CSC(=O)C#C SGWFGVQCRDTUQN-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101100339421 Gallus gallus HMGB1 gene Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101900330356 Influenza A virus Matrix protein 2 Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100038458 Ubinuclein-1 Human genes 0.000 description 1
- 101710094188 Ubinuclein-1 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB 1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.
Description
WO 2011,1091255 PCT/US2011/022062 VACCINE VECTORS AND METHODS OF ENHANCING IMMUNE RESPONSES
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application claims the benefit of priority of United States Provisional Patent Application No. 61/297,098, filed January 21. 2010, INTRODUCTION
Vaccines are used to initiate an adaptive immune response against antigens, in particular antigens from pathogens, tumor cells or the like, in order to ameliorate or prevent disease.
Synthetic peptides or killed or attenuated microorganism vaccines are often effective at stimulating a robust immune response that is fully protective. In sonic cases these vaccines are not protective or only partially protective and other strategies must be used to develop protective vaccines. Attenuated microorganism based vaccines also are associated with risks of gene transfer or mutation repair and may pose risks to immunocompromised individuals.
Development of new vaccines that are safe and effective at stimulating lasting protective immune responses is needed.
Influenza Virus infection, particularly avian in iltienza Fl5N1, presents a mounting health and economic concern. Evidence clearly indicates that 115N1 is continuing to circulate between susceptible birds and swine in widening regions of the world. Many scientists believe that if left unchecked, the current 115 NI avian influenza will mutate to allow for human to human transmission and cause a world-wide pandemic. With a mortality rifle of over 50%, such an outbreak would be devastating. Regardless of the ability of the virus to cause human disease, avian influenza H5N1 is already threatening to have a huge economic impact due to the eradication of poultry flocks in affected areas. Therefore, development of a vaccine to protect humans, poultry, swine and other domesticated animals from H5N1 influenza is needed. An influenza vaccine that is capable of protecting against H5N1 as well as other influenza viruses, such as H1N1, would be optimal.
SUMMARY
Vaccine vectors and methods of stimulating an immune response and methods of reducing morbidity associated with Influenza infection are provided herein. In one aspect, a vaccine vector including an antigenic polypeptide and an HMGB1 polypeptide or a functional fragment thereof is provided. At least a portion of the antigenic polypeptide and the HMGB1 polypeptide are present on the surface of the vaccine vector. The vaccine vector may include a first polynucleotide encoding the antigenic polypeptide and a second polynucleotide encoding the HMGB1 polypeptide. The HMGB1 polypeptide and the antigenic polypeptide may be .. linked, such as in a fusion protein. The HMGB1 polypeptide and the antigenic polypeptide may both be inserted within an external loop of a transmembrane protein.
In another aspect, a composition comprising the vaccine vector and a pharmaceutically acceptable carrier is provided. The pharmaceutically acceptable carrier may be acceptable for oral or nasal use. The vaccine vector may be incapable of replication.
In yet another aspect, a Bacillus spp. vaccine vector is provided. The vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide expressed on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide expressed on the surface of the vaccine vector.
The antigenic
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application claims the benefit of priority of United States Provisional Patent Application No. 61/297,098, filed January 21. 2010, INTRODUCTION
Vaccines are used to initiate an adaptive immune response against antigens, in particular antigens from pathogens, tumor cells or the like, in order to ameliorate or prevent disease.
Synthetic peptides or killed or attenuated microorganism vaccines are often effective at stimulating a robust immune response that is fully protective. In sonic cases these vaccines are not protective or only partially protective and other strategies must be used to develop protective vaccines. Attenuated microorganism based vaccines also are associated with risks of gene transfer or mutation repair and may pose risks to immunocompromised individuals.
Development of new vaccines that are safe and effective at stimulating lasting protective immune responses is needed.
Influenza Virus infection, particularly avian in iltienza Fl5N1, presents a mounting health and economic concern. Evidence clearly indicates that 115N1 is continuing to circulate between susceptible birds and swine in widening regions of the world. Many scientists believe that if left unchecked, the current 115 NI avian influenza will mutate to allow for human to human transmission and cause a world-wide pandemic. With a mortality rifle of over 50%, such an outbreak would be devastating. Regardless of the ability of the virus to cause human disease, avian influenza H5N1 is already threatening to have a huge economic impact due to the eradication of poultry flocks in affected areas. Therefore, development of a vaccine to protect humans, poultry, swine and other domesticated animals from H5N1 influenza is needed. An influenza vaccine that is capable of protecting against H5N1 as well as other influenza viruses, such as H1N1, would be optimal.
SUMMARY
Vaccine vectors and methods of stimulating an immune response and methods of reducing morbidity associated with Influenza infection are provided herein. In one aspect, a vaccine vector including an antigenic polypeptide and an HMGB1 polypeptide or a functional fragment thereof is provided. At least a portion of the antigenic polypeptide and the HMGB1 polypeptide are present on the surface of the vaccine vector. The vaccine vector may include a first polynucleotide encoding the antigenic polypeptide and a second polynucleotide encoding the HMGB1 polypeptide. The HMGB1 polypeptide and the antigenic polypeptide may be .. linked, such as in a fusion protein. The HMGB1 polypeptide and the antigenic polypeptide may both be inserted within an external loop of a transmembrane protein.
In another aspect, a composition comprising the vaccine vector and a pharmaceutically acceptable carrier is provided. The pharmaceutically acceptable carrier may be acceptable for oral or nasal use. The vaccine vector may be incapable of replication.
In yet another aspect, a Bacillus spp. vaccine vector is provided. The vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide expressed on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide expressed on the surface of the vaccine vector.
The antigenic
2 polypeptide may be an Influenza M2e polypeptide, an Influenza HA polypeptide, or an Influenza NP polypeptide or a combination thereof The immunostimulatory polypeptide may be a CD154 polypeptide or a HMGB1 polypeptide or a combination thereof The immunostimulatory polypeptide and the antigenic polypeptide may be linked, such as in a fusion protein and may be inserted with an external loop of a transmembrane protein.
In still another aspect, methods of enhancing an immune response in a subject are provided. In the method, the vaccine vectors or compositions provided herein are administered to the subject in an amount effective to enhance the immune response of the subject to the antigenic polypeptide. Suitably, the vaccine vector is administered orally or intranasally.
In a further aspect, methods of enhancing the immune response in a subject by administering a Bacillus spp. vaccine vector as described herein are provided.
The vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide expressed on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide expressed on the surface of the vaccine vector.
The antigenic polypeptide may be an Influenza M2e polypeptide, an Influenza HA polypeptide, an Influenza NP polypeptide or a combination thereof The immunostimulatory polypeptide may be a CD154 polypeptide, a HMGB1 polypeptide or a combination thereof.
In a still further aspect, methods of reducing influenza related morbidity in a subject are provided. In the methods, administration of the vaccine vectors or compositions disclosed herein reduces the morbidity associated with a subsequent influenza infection.
In still another aspect, methods of enhancing an immune response in a subject are provided. In the method, the vaccine vectors or compositions provided herein are administered to the subject in an amount effective to enhance the immune response of the subject to the antigenic polypeptide. Suitably, the vaccine vector is administered orally or intranasally.
In a further aspect, methods of enhancing the immune response in a subject by administering a Bacillus spp. vaccine vector as described herein are provided.
The vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide expressed on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide expressed on the surface of the vaccine vector.
The antigenic polypeptide may be an Influenza M2e polypeptide, an Influenza HA polypeptide, an Influenza NP polypeptide or a combination thereof The immunostimulatory polypeptide may be a CD154 polypeptide, a HMGB1 polypeptide or a combination thereof.
In a still further aspect, methods of reducing influenza related morbidity in a subject are provided. In the methods, administration of the vaccine vectors or compositions disclosed herein reduces the morbidity associated with a subsequent influenza infection.
3 BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a graph showing the S/P (sample to positive control) ratios of the ELISA for M2e specific antibody production by chickens after oral gavage of the indicated dosage of Bacillus subtilis vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.
Figure 2 is a graph showing the S/P ratios of the ELISA for HA LB specific antibody production by chickens after oral gavage of the indicated dosage of Bacillus subtilis vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.
Figure 3 is a graph showing the S/P ratios of the ELISA for HA UA specific antibody production by chickens after oral gavage of the indicated dosage of Bacillus subtilis vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.
Figure 4 is a graph showing the S/P ratios of the ELISA for M2e specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the Bacillus vector alone(BSBB).
Figure 5 is a graph showing the S/P ratios of the ELISA for HA LB specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the Bacillus vector alone(BSBB).
Figure 6 is a graph showing the S/P ratios of the ELISA for HA UA specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated
Figure 1 is a graph showing the S/P (sample to positive control) ratios of the ELISA for M2e specific antibody production by chickens after oral gavage of the indicated dosage of Bacillus subtilis vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.
Figure 2 is a graph showing the S/P ratios of the ELISA for HA LB specific antibody production by chickens after oral gavage of the indicated dosage of Bacillus subtilis vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.
Figure 3 is a graph showing the S/P ratios of the ELISA for HA UA specific antibody production by chickens after oral gavage of the indicated dosage of Bacillus subtilis vaccine vector expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with saline.
Figure 4 is a graph showing the S/P ratios of the ELISA for M2e specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the Bacillus vector alone(BSBB).
Figure 5 is a graph showing the S/P ratios of the ELISA for HA LB specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the Bacillus vector alone(BSBB).
Figure 6 is a graph showing the S/P ratios of the ELISA for HA UA specific antibody production by chickens after oral gavage of the indicated dosage of live or variously inactivated
4
5 PCT/US2011/022062 Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and either HMGB1 or CD154 as compared to chickens vaccinated with the Bacillus vector alone (BSBB).
Figure 7 is a graph showing the S/P ratios of the ELISA for M2e specific IgG
antibody production by chickens after oral gavage of either 106 live or the various indicated dosages of formalin inactivated Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the Bacillus vector alone (BSBB).
Figure 8 is a graph showing the S/P ratios of the ELISA for M2e specific IgA
antibody production by chickens vaccinated, either orally or subcutaneously, with 106 live, formalin inactivated or formalin inactivated and lyophilized Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the Bacillus vector alone (BSBB).
Figure 9 is a graph showing the S/P ratios of the ELISA for M2e specific IgA
antibody production by chickens vaccinated, either orally or subcutaneously, with 106 live, formalin inactivated or formalin inactivated and lyophilized Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the Bacillus vector alone (BSBB).
DETAILED DESCRIPTION
Recombinant DNA technologies enable relatively easy manipulation of many bacterial and viral species. Some bacteria and viruses are either naturally or can be selected or engineered to be mildly pathogenic or non-pathogenic, but remain capable of generating a robust immune response. These bacteria and viruses make attractive vaccine vectors for eliciting an immune response to heterologous or foreign antigens. Bacterial or viral vaccine vectors may mimic the natural infection and produce robust and long lasting immunity. Vaccine vectors are often relatively inexpensive to produce and administer. In addition, such vectors can often carry more than one antigen and may provide protection against multiple infectious agents.
Live bacterial or viral vaccine vectors may still pose risks to immunocompromised individuals and require additional regulatory scrutiny. Thus use of vectors that are killed or inactivated or qualify as Generally Regarded As Safe (GRAS) organisms by the Food and Drug Administration (FDA) is desirable. The problem is generating a robust immune response using such vectors. As shown in the Examples, by including HMGB1 (high mobility group box 1) polypeptides on the surface of the vaccine vector we can generate a robust immune response against antigenic polypeptides using a Bacillus spp. vector. In fact, the Examples demonstrate that this vector can be inactivated such that it cannot replicate using a variety of methods and still elicit a robust immune response after administration.
Vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide or a functional fragment thereof are provided herein. At least a portion of the antigenic polypeptide and at least a portion of the HMGB I polypeptide or functional fragment thereof are present on the surface of the vaccine vector. The vaccine vector may include a first polynucleotide encoding the antigenic polypeptide and a second polynucleotide encoding the polypeptide. The HMGB1 polypeptide and the antigenic polypeptide may be linked, such as in a fusion protein or may be expressed separately. The HMGB I polypeptide and the antigenic polypeptide may both be inserted within an external loop of a transmembrane protein.
The vaccine vectors may be bacterial, viral or liposome-based vectors.
Potential vaccine vectors include, but are not limited to, Bacillus (Bacillus subtilis), Salmonella (Salmonella enteritidis), Shigella, Escherichia (E. coli), Yersinia, Bordetella, Lactococcus, Streptococcus, Vibrio (Vibrio cholerae), Listeria, adenovirus, poxvirus, herpesvirus, alphavirus, and adeno-associated virus. Suitably, the vaccine vector is a GRAS organism. The vaccine vector may be inactivated or killed such that it is not capable of replicating. Methods of inactivating or killing bacterial or viral vaccine vectors are known to those of skill in the art and include, but are not limited to methods such as those shown in the Examples, namely formalin inactivation, antibiotic- based inactivation, heat treatment and ethanol treatment.
An antigenic polypeptide is a polypeptide that is capable of being specifically recognized by the adaptive immune system. An antigenic polypeptide includes any polypeptide that is immunogenic. The antigenic polypeptides include, but are not limited to, antigens that are pathogen-related, allergen-related, tumor-related or disease-related.
Pathogens include viral, parasitic, fungal and bacterial pathogens as well as protein pathogens such as the prions. The antigenic polypeptides may be full-length proteins or portions thereof. It is well established that immune system recognition of many proteins is based on a relatively small number of amino acids, often referred to as the epitope. Epitopes may be only 8-10 amino acids. Thus, the antigenic polypeptides described herein may be full-length proteins, 8 amino acid long epitopes or any portion between these extremes. In fact the antigenic polypeptide may include more than one epitope from a single pathogen or protein.
Multiple copies of the same epitope or multiple epitopes from different proteins may be included in the vaccine vector. It is envisioned that several epitopes or antigens from the same or different pathogens or diseases may be administered in combination in a single vaccine vector to generate an enhanced immune response against multiple antigens. Recombinant vaccine vectors may encode antigens from multiple pathogenic microorganisms, viruses or tumor associated antigens. Administration of vaccine vectors capable of expressing multiple antigens has the advantage of inducing immunity against two or more diseases at the same time.
The antigenic polypeptide may be an Influenza polypeptide, suitably it is an Influenza 1-15N1 polypeptide or a polypeptide associated with multiple strains of the Influenza virus such as a polypeptide of the Influenza M2 protein. The ectodomain of the Influenza A
virus M2 protein.
known as M2e, protrudes from the surface of the virus. The M2e portion of the M2 protein contains about 24 amino acids. The M2c polypeptide varies little front one isolate to the next within Influenza. In fact, only a few naturally occurring mutations in M2e have been isolated from infected humans since the 1918 flu epidemic, In addition, influenza viruses isolated from avian and swine hosts have different, yet still conserved, Mlle sequences. For reviews of the M2e polypeptide sequences isolated from human, avian and swine hosts sec Liu et al., Microbes .. and Infection 7:171-177 (2005) and Reid et al., J. Virol. 76:10717-10723 (2002). See also SEQ ID NO:1-4.
Suitably the entire M2e polypeptide may be inserted into the vaccine vector or only a portion may be used. In the Examples, an eight amino acid polypeptide (LM2 having amino acid sequence: EVEFPIRN, SEQ ID ',40:5 or its variant. 1\42cA having amino acid sequence EVEIPTRN, SEQ ID NO:61 was incorporated into the vaccine vector and demonstrated to produce an antibody response after administration to chickens. Suitably, the portion of the M2e polypeptide inserted into the vaccine vector is immunogenic, An immunogenic fragment is a peptide or polypeptidc capable of eliciting a cellular or Immoral immune response. Suitably, an immunogenic fragment of M2e may be the full-length M2e polypeptide, or suitably may be 20 or more amino acids, 15 or more amino acids, 10 or more amino acids or 8 or more amino acids of the hill-length sequence.
Other suitable epitopes for inclusion in an Influenza A vaccine vector include, but are not limited to, polypeptides of the hemagglutinin (HA) or the nuclear protein (NP) of Influenza A.
For example, the peptides of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID
NO:I0 maybe included in a vaccine vector. In the Examples, SEQ ID NO: 7 (HAUA) and SEQ ID NO:
8 (HAEB) were incorporated into the vaccine vector and demonstrated to produce an antibody response after administration, to chickens. Sec Figures 2-3 and 5-6. In addition, the NP epitopcs of SEQ ID NO: 9 (NP54) and SEQ ID NO: 10 (NPI47) were incorporated into the vaccine vector in the examples. One of skill in the art will appreciate that any of those sequences may be used in combination with any other epitope including epitopes derived from other pathogens or antigens.
The ['MGR! (High Mobility Group Box-1) protein was first identified as a DNA-binding .. protein critical Ibr DNA structure and stability. It is a ubiquitously expressed nuclear protein that hinds DNA with no sequence specificity. The protein is highly conserved and found in plants to mammals. The zebrafish, chicken and human HMGB1 amino acid sequences arc provided in SEQ ID NO: 30, SEQ ID NO: 18 and SEQ ID NO: 29, respectively. The sequence throughout mammals is highly conserved with 98% amino acid identity and the amino acid changes are conservative. Thus an I MICAH protein from one species can likely substitute liar that from another species functionally. The 11111-length HMGB1 protein or a portion thereof may be used as the HMGBI polypephde in the vaccine vectors described herein.
H.M6B1 has two DNA binding regions temied A box as shown in SEQ ID NO: 23 and 24 and B box as shown in SEQ ID NO: 25 and 26. See Andersson and TraccyõAnnit. Rev. Immunol. 2011, 29:
139-162.
HMGH I is a mediator of inflammation and serves as a signal of nuclear damage, such as From necrotic cells. HMGB I can also be actively secreted by cells of the monoeyteimacrophage lineage in a process requiring acetylation of the protein, translocation across the nucleus and WO 2011/11912Sfk vcr112s20 1/11221)62 secretion. Exton:el lular HIVICEBI acts as a potent mediator of inflammation by signaling via the Receptor fbr Advanced Glycated End-products (RAGE) and via members of the Toll-like Receptor family (TER.), in particular TL.R.4. The RAGE binding activity has been identified and requires the polypeptide of SEQ ID NO: 27. TER4 binding requires the cystcine at position 106 of SEQ ID NO: 18, which is found in the 13 box region al INIGB1.
The inflammatory activities of I IMG131 do not require the full-length protein and functional fragments have been identified. The 13 box has been shown to be sufficient to mediate the pro-inflanunatory effects of EIMGR1 and thus SEQ ID NO: 25 and 26 are polypeptides or functional fragments thereof within the context of the present invention. En addition, the RAGE binding site and the pro-inflanunatoty cytokine activity have been mapped to SE-7Q ID NO: 27 and SEQ ID NO: 28, respectively. Thus, these polypeptides are functional fragments of liMG131 polypeptides in the context of the present invention.
Those of skill in the art are capable of identifying HMGB 1 polypeptides and fragments thereof capable of stimulating pro-inflammatory cytokine activity, using methods such as those in International Publication No. W002 092004.
Suitably, the MAGRI polypeptide includes the RAGE binding domain at amino acids 150-183 of SEQ ID NO:18 (SEQ ID NO: 27 or a homolog thereof) and the pro-inflammatory cytokine activity domain between amino acids 89-109 of SEQ ID NO: 18 (SEQ ID
NO: 28 or a homolog thereof). In particular, 11141GBI polypeptides and functional fragments or homologs thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 95% identical, at least 90% identical, at least 85% identical, or at least 80%
identical to the HMGB1 polypeptides or SEQ ID NOs: 18 or 23-30.
At least a portion of the antigenic polypeptide and at least a portion of the polypeptide are present on the surface of the vaccine vector. Present on the surface of the vaccine vector includes polypeptides that are comprised within a transmembrane protein, interacting with, covalently or chemically cross-linked to a transmembrane protein, a membrane lipid or membrane anchored carbohydrate. A polypeptide can be comprised within a transmembrane protein by having the amino acids comprising the polypeptide linked via a peptide bond to the N-terminus, C-terminus or anywhere within the transmembrane protein (i.e.
inserted between two amino acids of the transmembrane protein or in place of one or more amino acids of the transmembrane protein (i.e. deletion-insertion). Suitably, the polypeptides may be inserted into an external loop of a transmembrane protein. Suitable transmembrane proteins are cotB and lamB , but those of skill in the art will appreciate many suitable transmembrane proteins are available.
Alternatively, the polypeptides may be covalently or chemically linked to proteins, lipids or carbohydrates in the membrane, or capsid if a viral vector is being used through methods available to persons of skill in the art. For example, di-sulfide bonds or biotin ¨ avidin cross-linking could be used to present the antigenic and HMGB1 polypeptides on the surface of a vaccine vector. Suitably, the antigenic polypeptide and the HMGB1 polypeptide are part of a fusion protein. The two polypeptides may be directly linked via a peptide bond or may be separated by a linker or a section of a third protein into which they are inserted.
Polynucleotides encoding the antigenic polypeptide or HMGB1 polypeptide may be inserted into the vaccine vector and expressed to generate the antigenic polypeptide and the HMGB1 polypeptide. The polynucleotides may be inserted into the chromosome of the vaccine vector or encoded on plasmids or other extrachromosomal DNA. Suitably, polynucleotides encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be expressed independently or are inserted into a vaccine vector polynucleotide that is expressed. Suitably, the vaccine vector polynucleotide encodes a polypeptide expressed on the surface of the vaccine vector such as a transmembrane protein. The polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be inserted into the vaccine vector polynucleotide sequence to allow expression of the antigenic polypeptide and/or the HMGB1 polypeptide on the surface of the vector. For example, the polynucleotide encoding the antigenic polypeptide and the HMGB1 polypeptide may be inserted in frame into a bacterial polynucleotide in a region encoding an external loop region of a transmembrane protein such that the bacterial polynucleotide sequence remains in frame. See Example 1.
Alternatively, the polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be inserted into a secreted polypeptide which is displayed or presented on the surface of the vaccine vector through association with a protein, lipid or carbohydrate on the surface of the vaccine vector. Those of skill in the art will appreciate that the polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide could be inserted in a wide variety of vaccine vector polynucleotides to provide expression and presentation of the antigenic polypeptide and/or the 1-IMGB1 polypeptide to the immune cells of a subject treated with the vaccine vector. In the Examples, several Influenza epitopes including an M2e epitope, a HA
epitope and a NP epitope were expressed from a plasmid for vegetative expression in Bacillus subtilis . The resulting recombinant bacteria express the inserted epitopes as demonstrated by the immune response shown in Figures 1-6.
In the Examples, the vaccine vectors have the antigenic polypeptides (M2c, HA
and NP
polypeptides) and the immunostimulatory polypeptide (either CD154 or HMGB1) encoded on the same polynucleotide and in frame with each other. In alternative embodiments, the immunostimulatory polypeptide and the antigenic polypeptide may be encoded by distinct polynucleotides. Those of skill in the art will appreciate that a variety of methods may be used to obtain expression of the antigenic polypeptide and the HMGB1 polypeptide on the surface of the vaccine vector. Such methods are known to those skilled in the art.
Compositions comprising the vaccine vector and a pharmaceutically acceptable carrier are also provided. A pharmaceutically acceptable carrier is any carrier suitable for in vivo administration. Suitably, the pharamaceutically acceptable carrier is acceptable for oral, nasal or mucosal delivery. The pharmaceutically acceptable carrier may include water, buffered solutions, glucose solutions or bacterial culture fluids. Additional components of the compositions may suitably include excipients such as stabilizers, preservatives, diluents, emulsifiers and lubricants. Examples of pharmaceutically acceptable carriers or diluents include stabilizers such as carbohydrates (e.g., sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein-containing agents such as bovine serum or skimmed milk and buffers (e.g., phosphate buffer). Especially when such stabilizers are added to the compositions, the composition is suitable for freeze-drying or spray-drying.
The vaccine vector in the compositions may not be capable of replication, suitably the vaccine vector is inactivated or killed prior to addition to the composition.
The compositions described herein may be used to enhance an immune response such as an antibody response to the antigenic polypeptide. The compositions containing Influenza polypeptides may also be used to decrease the morbidity associated with subsequent Influenza infection. The compositions may prevent Influenza from causing disease or any associated morbidity in a subject to which the compositions or vaccine vectors described herein were administered. The compositions and vaccine vectors described herein may reduce the severity of subsequent disease by decreasing the length of disease, decreasing the morbidity or mortality associated with the disease or reducing the likelihood of contracting the disease. The morbidity or mortality associated with the disease after administration of the vaccine vectors described herein may be reduced by 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100%
as compared to similar subjects not provided the vaccine vector.
Methods of enhancing immune responses in a subject by administering a vaccine vector are also provided. The vaccine vector may contain a HMGB1 polypeptide capable of stimulating the immune response to the vaccine vector and its associated antigenic polypeptide. The vaccine vector comprising a polypeptide of HMGB1 is administered to a subject in an amount effective to enhance the immune response of the subject to the vaccine and in particular to the antigenic polypeptide. Suitably, the vaccine vector contains a polynucleotide encoding a polypeptide including amino acids 150-183 and 89-109 of the HMGB1 polypeptide (SEQ ID NO:
18) or a homolog thereof In the Examples, a 190 amino acid polypeptide of HMGB1 was used.
Suitably, the polynucleotide encodes a HMGB1 polypeptide from the same species as the subject. Heterologous combinations of HMGB1 polypeptides and subjects (i.e. a human HMGB1 polypeptide for use in a chicken vaccine) may be useful in the methods of the invention because HMGB1 is highly conserved through a wide number of species. The HMGB1 polypeptide may be used to enhance the immune response in the subject to any foreign antigen or antigenic polypeptide present in or on the vaccine vector. One of skill in the art will appreciate that the HMGB1 polypeptide could be used to enhance the immune response to more than one antigenic polypeptide present in a vaccine vector. The polypeptide from HMGB1 stimulates an immune response at least in part by activating dendritic cells and macrophages and thus stimulating production of cytokines such as IL-1, IL-6, IFN-y and TNF-a. In the Examples, a polypeptide of HMGB1 was expressed on the surface of the vaccine vector.
In addition, methods of enhancing an immune response against influenza A and methods of reducing morbidity associated with subsequent Influenza A infection are disclosed. Briefly, the methods comprise administering to a subject a vaccine vector comprising an Influenza A
epitope (an antigenic polypeptide of Influenza) capable of eliciting an immune response in an amount effective to elicit the immune response. The Influenza A epitope may be a M2e polypeptide, an HA polypeptide or a NP polypeptide or another influenza polypeptide as discussed above. The insertion of the antigenic polypeptides into the vaccine vector may be accomplished in a variety of ways known to those of skill in the art, including but not limited to the scarless site-directed mutation system described in International Patent Publication No. WO
2008/036675. The bacterium may also be engineered to express Influenza polypeptides in conjunction with polynucleotides capable of enhancing the immune response as discussed above.
In particular, a polypeptide of CD154 or HMGB1 may be expressed by the vaccine vector to enhance the immune response of the subject to the influenza polypeptides. The Examples demonstrate production of a robust IgA and IgG response to vaccination in chickens. We expect that such a robust response will be protective against or at least reduce the morbidity associated with subsequent infection or challenge with the source of the antigenic polypeptide (Influenza virus in the Examples).
The compositions may be administered by a variety of means including, but not limited to, orally, intranasally, and mucosally. For example, the compositions or vaccine vectors may be delivered by aerosol, by spraying, by addition to food or water, by oral gavage, or via eye drops.
In some embodiments, the compositions are administered by injection such as intradermally, parenterally, subcutaneously, intraperitoneally, intravenously, intracranially, or intramuscularly.
For chickens or other poultry, the compositions may be administered in ovo.
Subjects include, but are not limited to, a vertebrate, suitably a mammal, suitably a human, cows, cats, dogs, pigs, or birds, suitably poultry such as chickens.
Other animal models of infection may also be used. Enhancing an immune response includes, but is not limited to, inducing a therapeutic or prophylactic effect that is mediated by the immune system of the subject. Specifically, enhancing an immune response may include enhanced production of antibodies, such as demonstrated in Figures 1-3, enhanced class switching of antibody heavy chains such as production of IgA as shown in Figure 8, maturation of antigen presenting cells, stimulation of helper T cells, stimulation of cytolytic T cells or induction of T and B cell memory.
The useful dosage to be administered will vary depending on the age, weight and species of the subject, the mode and route of administration and the type of pathogen or disease against which an immune response is sought. The composition may be administered in any dose of vaccine vector sufficient to evoke an immune response. It is envisioned that doses ranging from 103 to 1010 vector copies (i.e. plaque forming or colony forming units), from 104 to 109 vector copies, or from 105 to 107 vector copies are suitable.
The composition may be administered only once or may be administered two or more times to increase the immune response. For example, the composition may be administered two or more times separated by one week, two weeks, or by three weeks, one month, two months, three months, six months or more. The bacteria may be viable prior to administration, but in some embodiments the bacteria may be killed or inactivated prior to administration. In some embodiments, the bacteria may be able to replicate in the subject, while in other embodiments the bacteria may not be capable of replicating in the subject. As shown in the Examples, bacterial vaccine vectors may be inactivated prior to administration using formalin, ethanol, heat or antibiotics. One skilled in the art would appreciate other means of inactivating vaccine vectors could be used as well.
A Bacillus spp. vaccine vector is also provided herein. The Bacillus vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide and a second polynucleotide sequence encoding an immunostimulatory polypeptide.
The antigenic polypeptide and the immunostimulatory polypeptide are present on the surface of the Bacillus vaccine vector as described above. The antigenic polypeptide is an Influenza polypeptide as described above and the immunostimulatory polypeptide is a HMGB1 polypeptide as described above or a CD154 polypeptide.
Polynucleotides encoding immunostimulatory polypeptides that are homologous to proteins of the subject and capable of stimulating the immune system to respond to the antigenic polypeptide may also be inserted into a vaccine vector. As described in more detail in the Examples, a vaccine vector may include a CD154 polypeptide that is capable of binding CD40 in the subject and stimulating the subject to respond to the vaccine vector and its associated antigenic polypeptide, similar to 1-1MGB1 described above. The Bacillus vaccine vector may include a HMGB1 polypeptide, a CD154 polypeptide or a combination thereof. As described above, polynucleotides encoding these polypeptides may be inserted into the chromosome of the vaccine vector or maintained extrachromosomally. One of skill in the art will appreciate that these polypeptides can be inserted in a variety of polypeptides of the vaccine vector and expressed in different parts of the vaccine vector or may be secreted.
The polynucleotide encoding an immunostimulatory polypeptide capable of enhancing the immune response to an antigenic polypeptide may also encode the antigenic polypeptide.
The polynucleotide encoding an immunostimulatory polypeptide may be linked to the polynucleotide encoding the antigenic polypeptide, such that in the vaccine vector the immunostimulatory polypeptide and the antigenic polypeptide are encoded by the same polynucleotide. In the Examples, a polynucleotide encoding a polypeptide of CD154, which is capable of binding to CD40, or HMGB1 also encodes an M2e epitope, an HA
epitope and a NP
epitope of Influenza A. See SEQ ID NOs: 19-22. In the Examples, the polynucleotide encoding the Influenza epitopes and the polynucleotide encoding the immunostimulatory polypeptide are both expressed from a plasmid for vegetative cell expression. In some embodiments, the polynucleotides are inserted in the cotB gene or another gene encoding a protein expressed on the surface of spores. Those of skill in the art will appreciate that bacterial polynucleotides encoding other transmembrane proteins may also be used.
As discussed above, a polynucleotide encoding an immunostimulatory polypeptide homologous to a protein of the subject that is capable of enhancing the immune response to the epitope may be included in the vaccine vector. In the Examples, a Bacillus vaccine vector including a polynucleotide encoding either a CD154 polypeptide capable of binding to CD40 or a polypeptide encoding HMGB1 were demonstrated to enhance the immune response to the M2e epitope and to two distinct HA epitopes as measured by increased antibody production in response to vaccination.
Suitably, the CD154 polypeptide is fewer than 50 amino acids long, more suitable fewer than 40, fewer than 30 or fewer than 20 amino acids in length. The polypeptide may be between 10 and 15 amino acids, between 10 and 20 amino acids or between 10 and 25 amino acids in length. The CD154 sequence and CD40 binding region are not highly conserved among the various species. The CD154 sequences of chicken and human are provided in SEQ
ID NO: 11 and SEQ ID NO: 12, respectively.
The CD40 binding regions of CD154 have been determined for a number of species, .. including human, chicken, duck, mouse and cattle and are shown in SEQ ID
NO: 13, SEQ ID
NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, respectively. Although there is variability in the sequences in the CD40 binding region between species, the Examples below indicate that the human CD154 polypeptide was able to enhance the immune response in chickens. Therefore, one may practice the invention using species specific CD154 polypeptides or a heterologous CD 154 polypeptide. In particular, CD154 polypeptides and functional fragments or homologs thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 95% identical, at least 90% identical, at least 85% identical, or at least 80% identical to the CD154 polypeptides of SEQ ID NOs: 11-17.
The Bacillus vaccine vector described herein may be used in the methods of enhancing an immune response and the methods of reducing Influenza morbidity in a subject as described above. The Bacillus vaccine vector may be used to make compositions for administration to subjects such as those described above as well.
Heterologous polynucleotides encoding antigenic polypeptides can be inserted in the bacterial genome at any non-essential site or alternatively may be carried on a plasmid using methods well known in the art. One suitable site for insertion of polynucleotides is within external portions of transmembrane proteins or coupled to sequences which target the hcterologous polynucleotide for secretory pathways. Examples of a suitable transmembrane protein for insertion of polynucleotides are the cotB gene of Bacillus and the lamB gene of Salmonella.
Heterologous polynucleotides include, but are not limited to, polynucleotides encoding antigens selected from pathogenic microorganisms or viruses other than the vaccine vector.
Such polynucleotides may be derived from pathogenic viruses such as influenza (e.g., M2e, hemagglutinin, or neuraminidase), herpesviruses (e.g., the genes encoding the structural proteins of herpesviruses), retroviruses (e.g., the gp160 envelope protein), adenoviruses, paramyxoviruses, coronaviruses and the like. Heterologous polynucleotides can also be obtained from pathogenic bacteria, e.g., genes encoding bacterial proteins such as toxins, and outer membrane proteins. Further, heterologous polynucleotides from parasites, such as Eimeria are attractive candidates for use in a vector vaccine.
Additional immunostimulatory polypeptides involved in triggering the immune system may also be included in the vaccine vectors described herein. The polynucleotides may encode immune system molecules known for their stimulatory effects, such as an interleukin, Tumor Necrosis Factor or an interferon, or another polynucleotide involved in immune-regulation.
The following examples are meant only to be illustrative and are not meant as limitations on the scope of the invention or of the appended claims.
EXAMPLES
Example 1. Construction of HA/NP/M2e/cCD154 and HA/NP/M2e/HMGB1 Bacillus vectors.
Strains and Culture Conditions All plasmids were first maintained in TOP10 E. coli cells (Invitrogen, Carlsbad, CA, USA) unless described otherwise. Bacillus spp. was used for introduction of mutations (Bacillus subtilis, Poultry Health Laboratory strain designated as NP122).
Bacteria carrying plasmid pDGIEF and pHT10 were grown at 37 C.
Luria-Bertani (LB) media was used for routine growth of cells, and SOC media (Invitrogen, Carlsbad, CA, USA) was used for phenotypic expression after electroporation.
When appropriate, the following were added to the media:
Isopropy1-13-D-thiogalactopyranoside (IPTG) at 1m1V1, ampicillin (Amp) at 100 g/ml, spectinomycin (SP) at 100 g/ml, and chloramphenicol (Cm) at 5tig/ml.
Plasmids Plasmids pDGIEF (Bacillus Genetic Stock Center, Columbus, OH) and pHT10 used for the present study were described previously (Zhang et al., Nuc. Acids Research 2006, 34 (9):1-8 and Nguyen et al., Curr. Micro. 2007, 55:89-93). Plasmid pDGIEF served as a template for amplification of the mcaF gene which was used as the counter-selectable marker during Bacillus chromosomal manipulation. Plasmid pHT10 was used to code for and produce the heterologous epitope sequences for Avian Influenza within Bacillus spp. This plasmid contains a CM
resistance gene, is induced by the addition of 1mM IPTG, and is maintained within Bacillus at 37 C.
Production of Heterologous Proteins for Vegetative Cell Expression:
Plasmid pHT10 purchased from MoBioTec/Boca Scientific, Boca Raton, FL (Nguyen et al., 2007) was transformed at the multiple cloning site by addition of a Bacillus subtilis codon optimized insertion sequence. DNA sequencing was done to confirm correct sequence insertion.
The newly modified plasmid was then transformed into Bacillus. Briefly, Bacillus cultures were grown overnight at 37 C in HS media (Spizizcn's medium supplemented with 0.5%
glucose, 50 g/m1 DL-tryptophan, 5014/m1 uracil, 0.02% casein hydrolysate, 0.1% yeast extract, 8p,g/m1 arginine, 0.4 g/m1 histidine, 1mM MgSO4). The overnight culture (1 ml) was used to inoculate 20m1 LS medium (Spizizen's medium supplemented with 0.5% glucose, 5 g/m1 DL-tryptophane, 5 g/m1 uracil, 0.01% casein hydrolysate, 0.1% yeast extract, 1mM
MgSO4, 2.5mM
MgCl2, 0.5mM CaCl2) and incubated with shaking for 3-4 hours at 30 C. To 1 ml of the resulting LS culture 10111 of 0.1M EGTA was added and incubated at room temperature for 5 minutes. Then 1-2 pig plasmid DNA was added, shaken for 2 hours at 37 C, and plated on LB
plates with selective antibiotics. These transformed Bacillus spp. now produce heterologous epitope sequences from AT when induced with 1mM IPTG.
PCR
All primers used for PCR are listed in Table 1. Typical PCR conditions consisted of approximately 0.11ag of purified genomic, plasmid or PCR-generated DNA
(Qiagen, Valencia, CA, USA), lx Pfu polymerase buffer, 5U Pfu polymerase (Stratagene La Jolla, CA, USA), 1mM
dNTPs (GE Healthcare Bio-Sciences Corp., Piscataway, NJ), 1.204 of each primer in a total volume of 50 4. The DNA engine thermal cycler (Bio-Rad, Hercules, CA, USA) was used with the following amplification conditions: 94 C for 2 minutes; 30 cycles of 94 C sec for 30 sec, 58 C for 60 sec, 72 C for 90 sec per 1 kb; and 72 C for 10 minutes for final extension.
Each PCR product was gel purified (Qiagen, Valencia, CA, USA) and either eluted in 254 EB
buffer for preparation of templates used in overlapping extension PCR or in 504 EB buffer, ethanol precipitated and suspended in 54 of ddE120 for electroporation into Bacillus spp.
Table 1: Primer sequences used to generate the vaccine vector Primer Amplified Primer Sequence (SEQ ID NO:) Region mazF for ilfazF gene 5' ctaaaatcttcagatgatcaatcatcctoactgcccgctttccagtogggaaa3' (SEQ ID NO: 31) mazF rev MazF gene 5'tgaacgtgacgaacgaccagatacccectatgcaagggtttat3' (SEQ ID NO: 32) CotB up for Cot B up 5' gaaatgctcgatgctgatga 3' (SEQ ID NO: 33) Cot B up rev Cot B up 5'ggatgattgatcatctgaagattttag3' (SEQ ID NO: 34) Cot B dn for Cot B down 5'aaatctggtcgttcgtcacgttca3' (SEQ ID NO: 35) Cot B dn rev Cot B down 5' ttacgtttccagtgatagtctatcg3' (SEQ ID NO: 36) 5'aaccattetttcaattgtaattgaattttgaatcagtctgcctgatgatgacagttettcataatcattaaaatc for CotB up gcccggatagcacagatcatttgccggatttgctgatgatgaatccatgcctgttctaaccagtgctcttgttc tttgatatgt ggatgattgatcatctgaagattttag3' (SEQ ID NO: 37) 5'ttacaattgaaagaatggttctgteatcatcatcactgctgtcaagaattaatcattttgaaaaaattcaatcat rev CotB down catcagaagttgaaacaccgattagaaattcatcateatggatgacaacatcatatgcaccgacatcatcatca tcagaagttgaaacaccgattagaaataaatctggtcgttcgtcacgtica3' (SEQ ID NO: 38) BS/Al/CD154 BS/AI/CD154 5'ttcaaaatgattaattettgacagcagtgatgatgatgacagaaccattctitcaattgtaattgaattttgaat for CotB up cagtctgcctgatgatgacagttcttcataatcattaaaatcgcccggatagcacagatcatttgccggatttg cggatgattgatcatctgaagattttag3 ' (SEQ ID NO: 39) BS/Al/CD154 BS/AI/CD154 5'caagaattaatcattttgaaaaaattcaatcatcatcagaagttgaaacaccgattagaaattcatcatcactgaaa rev CotB down gaaaaatatgaaaaagatattgcagcatatagagcaaaaggcaaagttgatgcaggcaaaaaagttgttgcaaa agcagaaaaatcaaaaaaaaaatctggtcgttcgtcacgttca3 ' (SEQ ID NO: 40) In Table 1, italicized nucleotides are those which are complementary to either side of the CotB
gene insertion site of Bacillus subtilis.
Electroporation Briefly, cells were inoculated into 10 ml. of LB broth and grown at 37 C
overnight.
Then 1004 of overnight culture was re-inoculated into 10mL fresh LB broth at 37 C for 3-4 hours. Cells were washed five times in ddH20 water and resuspended in 604 of 10% glycerol.
Cells were then pulsed at 2.4-2.45kV for 1-6ms, incubated in 0.5m1 SOC for 2-3 hours at 37 C
and plated on LB media with appropriate antibiotics.
Chromosomal Integration of Heterologous DNA for Spore Coat Expression:
Recombinant Bacillus strains containing stable integrated copies of selected M2e, HA
and NP epitopes were constructed using recently published methods with modification. Briefly, Bacillus strains were transformed with the MazF cassette (Zhang et al., 2006) which generated a strain which was IPTG sensitive and spectomycin resistant. The MazF cassette flanked by approximately 300bp of homologous DNA on each side was introduced into the CotB gene (Isticato et al., 2001) of the Bacillus vector by electroporation followed by growth on media containing spectomycin for positive clones which now contain the MazF cassette which is spectomycin resistant.
After the MazF mutation was confirmed in CotB, this region was replaced by a codon-optimized DNA sequence coding for the antigenic epitopes of Al again flanked by 300 bp of homologous DNA. This was done by creating a PCR product using overlapping and extension PCR to produce the antigenic sequences flanked by approximately 300bp on each side homologous to the Bacillus chromosome (Cox et al., 2007). The PCR product was introduced into the Bacillus again by electroporation and replacement of the MazF
cassette. Transformants were selected on plates containing TPTG, positive clones should now be unresponsive to IPTG
and sensitive to spectomycin. Correct chromosomal sequence insertion was confirmed by DNA
sequencing.
Example 2. Vaccination Study I and 2.
Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=15/treatment group, Exp 1 and n=20/treatment group, Exp 2). All chicks in each treatment group were tagged and numbered.
The chicks were orally infected by gavage with 0.25 ml of saline or 106-108 cfu/ml of the various Bacillus treatments as indicated in Table 2 for study 1 and in Table 3 for study 2.
Table 2. Challenge Dose for each treatment group in Vaccination Study 1.
Treatment Group Challenge Dose Saline only BS/Al/HMGB1 106 cfu/ml BS/Al/HMGB1 108 cfu/ml BS/Al/CD154 106 cfu/ml BS/Al/CD154 108 cfu/ml Table 3. Challenge Dose for each treatment group in Vaccination Study 2.
Treatment Group Challenge Dose BSBB (Bacillus) 106 cfu/ml BS/Al/HMGB1 106 cfu/ml BS/Al/CD154 106 cfu/ml BS/Al/HMGB1 Heat Inactivated 106 cfu/ml BS/AI/HMGB1 Formalin Inactivated 106 cfu/ml BS/Al/HMGB1 Antibiotic Inactivated 106 cfu/ml BS/AI/HMGB1 Ethanol Inactivated 106 cfu/ml In study 2, the bacteria were inactivated in several different ways to assess whether replication was necessary for production of an antibody response directed to the antigenic influenza peptides. Several means of inactivation were used because the means of inactivation could result in destruction of the epitope and result in misinterpretation of the data and supporting a need for replication or viability of the Bacillus vector. The bacteria were inactivated by incubation for 10 minutes in 0.022% formalin (formalin inactivated); incubation for 10 minutes at 70 C (heat inactivated); incubation in 5lig/m1 gentamycin (antibiotic inactivated); or incubation for 10 minutes in 70% ethanol (ethanol inactivated).
Each treatment group was housed in an individual floor pen on fresh pine litter and provided water and feed ad libitum. On days 11 and 21 post-hatch, the birds were given a booster vaccine of the same treatment they received on Day 0. Also on days 21 and 31/32, blood was collected from each of the tagged birds and the serum was removed.
The serum collected from the tagged birds in each treatment group was then used in an antibody capture ELISA to determine specific M2e, HAUA and HALB antibody response. In brief, individual wells of a 96-well plate were coated with 10 g/m1 of the M2e epitope, HAUA
epitope or HALB epitope conjugated to BSA. Antigen adhesion was allowed to proceed overnight at 4 C. Plates were rinsed with PBS + 0.05% Tween 20, blocked with PBS
Superblock (Pierce Chemical Co.) for a minimum of 2 hours and incubated for 2 hours with the serum previously collected from the birds in each of the treatment groups described above. The plates were rinsed with PBS + 0.05% Tween 20 followed by incubation with peroxidase conjugated Goat-anti-Chicken IgY secondary antibody (1:7,500 dilution) obtained from Jackson ImmunoResearch Laboratories (West Grove, PA) for an additional hour. After subsequent rinsing, the plates were developed using a peroxidase substrate kit obtained from Fisher Scientific and absorbances read on a spectrophotometer at 450nm and 405nm.
Pooled serum samples from the groups receiving the vectored vaccine were used as positive controls and pooled serum samples from the unvaccinated groups were used as negative controls on each plate to replace the serum from the treatment groups. The absorbances obtained for the positive control, negative control and experimental samples were used to calculate Sample to Positive control ratios (S/P ratios) using the following calculation:
SIP ratio calculation: sample mean ¨ negative control mean positive control mean ¨ negative control mean The calculated S/P ratios for each study are shown in Figures 1-6. Figures 1-3 show the total antibody titers for M2e, HALB and HAUA for study 1, respectively, at days 21 and 31 post-hatch. The results demonstrate that robust immune responses to each of these antigens were generated after oral administration with a Bacillus expressing each of the epitopes with either CD154 of HMGB1 as the immunostimulatory peptide. Figures 4-6 show the total antibody titers for M2e, HALB and HAUA for study 2, respectively, at days 21 and 32 post-hatch. The results demonstrate that robust immune responses to each of the epitopes were generated after oral administration of a live Bacillus expressing the epitope and an immunostimulatory peptide.
Figures 4-6 also demonstrate that similar levels of specific antibodies were generated when the vector (the Bacillus) was inactivated prior to administration.
Example 3. Vaccination Study 3 Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=20/treatment group). All chicks in each treatment group were tagged and numbered. The chicks were orally infected by gavage with 0.25 ml of saline or 105-108 cfu/m1 of the Bacillus vector (BSBB), the Bacillus vector expressing the avian influenza epitopes and HMGB1 (BS/AI/HMGB1), or various amounts of the vector after formalin inactivation (as described above). On day 10 post-hatch, the birds were given a booster vaccine of the same treatment they received on Day 0. Also on days 21 and 32, blood was collected from each of the tagged birds and the serum was removed.
The serum IgG
M2e specific antibody levels were determined using the method described above with a peroxidase labeled anti-chicken TgG specific secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). The results in Figure 7 show that the formalin inactivated bacteria were able to stimulate production of M2e specific IgG antibodies as well as live bacteria. This result was surprising because it was generally believed that only live bacteria could stimulate a robust immune response after oral administration.
Example 4. Vaccination Study 4 Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=20-35/treatment group). All chicks in each treatment group were tagged and numbered. The chicks were orally infected by gavage or injected sub-cutaneously with 0.25 ml of 106 cfu/ml of the Bacillus vector (BSBB), the Bacillus vector expressing the avian influenza epitopes and HMGB1 (BSAI), or the BSAI
vector after formalin inactivation (as described above) or after formalin inactivation followed by lyophilization (reconstituted with saline immediately prior to administration). On day 10 post-hatch, some of the birds were given a booster vaccine of the same treatment they received on .. Day 0. On days 11, 14 and 21, blood was collected from each of the tagged birds and the serum was removed. The serum IgA and IgG M2e specific antibody levels were determined using the method described above with a perioxidase labeled anti-chicken IgA (GenTex) or a perioxidase labeled anti-chicken TgG specific secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). The results in Figure 8 show that the formalin inactivated bacteria were able to stimulate production of M2e specific IgA antibodies about as well as live bacteria when given orally. In contrast when given sub-cutaneously the inactivated BSAI vector was not as efficient at stimulating an IgA antibody response and the lyophilized bacteria did not stimulate an IgA
response. The results in Figure 9 show that each of the BSAI administration protocols supported robust IgG formation.
Figure 7 is a graph showing the S/P ratios of the ELISA for M2e specific IgG
antibody production by chickens after oral gavage of either 106 live or the various indicated dosages of formalin inactivated Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the Bacillus vector alone (BSBB).
Figure 8 is a graph showing the S/P ratios of the ELISA for M2e specific IgA
antibody production by chickens vaccinated, either orally or subcutaneously, with 106 live, formalin inactivated or formalin inactivated and lyophilized Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the Bacillus vector alone (BSBB).
Figure 9 is a graph showing the S/P ratios of the ELISA for M2e specific IgA
antibody production by chickens vaccinated, either orally or subcutaneously, with 106 live, formalin inactivated or formalin inactivated and lyophilized Bacillus subtilis vaccine vectors expressing the Influenza A epitopes and HMGB1 as compared to chickens vaccinated with the Bacillus vector alone (BSBB).
DETAILED DESCRIPTION
Recombinant DNA technologies enable relatively easy manipulation of many bacterial and viral species. Some bacteria and viruses are either naturally or can be selected or engineered to be mildly pathogenic or non-pathogenic, but remain capable of generating a robust immune response. These bacteria and viruses make attractive vaccine vectors for eliciting an immune response to heterologous or foreign antigens. Bacterial or viral vaccine vectors may mimic the natural infection and produce robust and long lasting immunity. Vaccine vectors are often relatively inexpensive to produce and administer. In addition, such vectors can often carry more than one antigen and may provide protection against multiple infectious agents.
Live bacterial or viral vaccine vectors may still pose risks to immunocompromised individuals and require additional regulatory scrutiny. Thus use of vectors that are killed or inactivated or qualify as Generally Regarded As Safe (GRAS) organisms by the Food and Drug Administration (FDA) is desirable. The problem is generating a robust immune response using such vectors. As shown in the Examples, by including HMGB1 (high mobility group box 1) polypeptides on the surface of the vaccine vector we can generate a robust immune response against antigenic polypeptides using a Bacillus spp. vector. In fact, the Examples demonstrate that this vector can be inactivated such that it cannot replicate using a variety of methods and still elicit a robust immune response after administration.
Vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide or a functional fragment thereof are provided herein. At least a portion of the antigenic polypeptide and at least a portion of the HMGB I polypeptide or functional fragment thereof are present on the surface of the vaccine vector. The vaccine vector may include a first polynucleotide encoding the antigenic polypeptide and a second polynucleotide encoding the polypeptide. The HMGB1 polypeptide and the antigenic polypeptide may be linked, such as in a fusion protein or may be expressed separately. The HMGB I polypeptide and the antigenic polypeptide may both be inserted within an external loop of a transmembrane protein.
The vaccine vectors may be bacterial, viral or liposome-based vectors.
Potential vaccine vectors include, but are not limited to, Bacillus (Bacillus subtilis), Salmonella (Salmonella enteritidis), Shigella, Escherichia (E. coli), Yersinia, Bordetella, Lactococcus, Streptococcus, Vibrio (Vibrio cholerae), Listeria, adenovirus, poxvirus, herpesvirus, alphavirus, and adeno-associated virus. Suitably, the vaccine vector is a GRAS organism. The vaccine vector may be inactivated or killed such that it is not capable of replicating. Methods of inactivating or killing bacterial or viral vaccine vectors are known to those of skill in the art and include, but are not limited to methods such as those shown in the Examples, namely formalin inactivation, antibiotic- based inactivation, heat treatment and ethanol treatment.
An antigenic polypeptide is a polypeptide that is capable of being specifically recognized by the adaptive immune system. An antigenic polypeptide includes any polypeptide that is immunogenic. The antigenic polypeptides include, but are not limited to, antigens that are pathogen-related, allergen-related, tumor-related or disease-related.
Pathogens include viral, parasitic, fungal and bacterial pathogens as well as protein pathogens such as the prions. The antigenic polypeptides may be full-length proteins or portions thereof. It is well established that immune system recognition of many proteins is based on a relatively small number of amino acids, often referred to as the epitope. Epitopes may be only 8-10 amino acids. Thus, the antigenic polypeptides described herein may be full-length proteins, 8 amino acid long epitopes or any portion between these extremes. In fact the antigenic polypeptide may include more than one epitope from a single pathogen or protein.
Multiple copies of the same epitope or multiple epitopes from different proteins may be included in the vaccine vector. It is envisioned that several epitopes or antigens from the same or different pathogens or diseases may be administered in combination in a single vaccine vector to generate an enhanced immune response against multiple antigens. Recombinant vaccine vectors may encode antigens from multiple pathogenic microorganisms, viruses or tumor associated antigens. Administration of vaccine vectors capable of expressing multiple antigens has the advantage of inducing immunity against two or more diseases at the same time.
The antigenic polypeptide may be an Influenza polypeptide, suitably it is an Influenza 1-15N1 polypeptide or a polypeptide associated with multiple strains of the Influenza virus such as a polypeptide of the Influenza M2 protein. The ectodomain of the Influenza A
virus M2 protein.
known as M2e, protrudes from the surface of the virus. The M2e portion of the M2 protein contains about 24 amino acids. The M2c polypeptide varies little front one isolate to the next within Influenza. In fact, only a few naturally occurring mutations in M2e have been isolated from infected humans since the 1918 flu epidemic, In addition, influenza viruses isolated from avian and swine hosts have different, yet still conserved, Mlle sequences. For reviews of the M2e polypeptide sequences isolated from human, avian and swine hosts sec Liu et al., Microbes .. and Infection 7:171-177 (2005) and Reid et al., J. Virol. 76:10717-10723 (2002). See also SEQ ID NO:1-4.
Suitably the entire M2e polypeptide may be inserted into the vaccine vector or only a portion may be used. In the Examples, an eight amino acid polypeptide (LM2 having amino acid sequence: EVEFPIRN, SEQ ID ',40:5 or its variant. 1\42cA having amino acid sequence EVEIPTRN, SEQ ID NO:61 was incorporated into the vaccine vector and demonstrated to produce an antibody response after administration to chickens. Suitably, the portion of the M2e polypeptide inserted into the vaccine vector is immunogenic, An immunogenic fragment is a peptide or polypeptidc capable of eliciting a cellular or Immoral immune response. Suitably, an immunogenic fragment of M2e may be the full-length M2e polypeptide, or suitably may be 20 or more amino acids, 15 or more amino acids, 10 or more amino acids or 8 or more amino acids of the hill-length sequence.
Other suitable epitopes for inclusion in an Influenza A vaccine vector include, but are not limited to, polypeptides of the hemagglutinin (HA) or the nuclear protein (NP) of Influenza A.
For example, the peptides of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID
NO:I0 maybe included in a vaccine vector. In the Examples, SEQ ID NO: 7 (HAUA) and SEQ ID NO:
8 (HAEB) were incorporated into the vaccine vector and demonstrated to produce an antibody response after administration, to chickens. Sec Figures 2-3 and 5-6. In addition, the NP epitopcs of SEQ ID NO: 9 (NP54) and SEQ ID NO: 10 (NPI47) were incorporated into the vaccine vector in the examples. One of skill in the art will appreciate that any of those sequences may be used in combination with any other epitope including epitopes derived from other pathogens or antigens.
The ['MGR! (High Mobility Group Box-1) protein was first identified as a DNA-binding .. protein critical Ibr DNA structure and stability. It is a ubiquitously expressed nuclear protein that hinds DNA with no sequence specificity. The protein is highly conserved and found in plants to mammals. The zebrafish, chicken and human HMGB1 amino acid sequences arc provided in SEQ ID NO: 30, SEQ ID NO: 18 and SEQ ID NO: 29, respectively. The sequence throughout mammals is highly conserved with 98% amino acid identity and the amino acid changes are conservative. Thus an I MICAH protein from one species can likely substitute liar that from another species functionally. The 11111-length HMGB1 protein or a portion thereof may be used as the HMGBI polypephde in the vaccine vectors described herein.
H.M6B1 has two DNA binding regions temied A box as shown in SEQ ID NO: 23 and 24 and B box as shown in SEQ ID NO: 25 and 26. See Andersson and TraccyõAnnit. Rev. Immunol. 2011, 29:
139-162.
HMGH I is a mediator of inflammation and serves as a signal of nuclear damage, such as From necrotic cells. HMGB I can also be actively secreted by cells of the monoeyteimacrophage lineage in a process requiring acetylation of the protein, translocation across the nucleus and WO 2011/11912Sfk vcr112s20 1/11221)62 secretion. Exton:el lular HIVICEBI acts as a potent mediator of inflammation by signaling via the Receptor fbr Advanced Glycated End-products (RAGE) and via members of the Toll-like Receptor family (TER.), in particular TL.R.4. The RAGE binding activity has been identified and requires the polypeptide of SEQ ID NO: 27. TER4 binding requires the cystcine at position 106 of SEQ ID NO: 18, which is found in the 13 box region al INIGB1.
The inflammatory activities of I IMG131 do not require the full-length protein and functional fragments have been identified. The 13 box has been shown to be sufficient to mediate the pro-inflanunatory effects of EIMGR1 and thus SEQ ID NO: 25 and 26 are polypeptides or functional fragments thereof within the context of the present invention. En addition, the RAGE binding site and the pro-inflanunatoty cytokine activity have been mapped to SE-7Q ID NO: 27 and SEQ ID NO: 28, respectively. Thus, these polypeptides are functional fragments of liMG131 polypeptides in the context of the present invention.
Those of skill in the art are capable of identifying HMGB 1 polypeptides and fragments thereof capable of stimulating pro-inflammatory cytokine activity, using methods such as those in International Publication No. W002 092004.
Suitably, the MAGRI polypeptide includes the RAGE binding domain at amino acids 150-183 of SEQ ID NO:18 (SEQ ID NO: 27 or a homolog thereof) and the pro-inflammatory cytokine activity domain between amino acids 89-109 of SEQ ID NO: 18 (SEQ ID
NO: 28 or a homolog thereof). In particular, 11141GBI polypeptides and functional fragments or homologs thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 95% identical, at least 90% identical, at least 85% identical, or at least 80%
identical to the HMGB1 polypeptides or SEQ ID NOs: 18 or 23-30.
At least a portion of the antigenic polypeptide and at least a portion of the polypeptide are present on the surface of the vaccine vector. Present on the surface of the vaccine vector includes polypeptides that are comprised within a transmembrane protein, interacting with, covalently or chemically cross-linked to a transmembrane protein, a membrane lipid or membrane anchored carbohydrate. A polypeptide can be comprised within a transmembrane protein by having the amino acids comprising the polypeptide linked via a peptide bond to the N-terminus, C-terminus or anywhere within the transmembrane protein (i.e.
inserted between two amino acids of the transmembrane protein or in place of one or more amino acids of the transmembrane protein (i.e. deletion-insertion). Suitably, the polypeptides may be inserted into an external loop of a transmembrane protein. Suitable transmembrane proteins are cotB and lamB , but those of skill in the art will appreciate many suitable transmembrane proteins are available.
Alternatively, the polypeptides may be covalently or chemically linked to proteins, lipids or carbohydrates in the membrane, or capsid if a viral vector is being used through methods available to persons of skill in the art. For example, di-sulfide bonds or biotin ¨ avidin cross-linking could be used to present the antigenic and HMGB1 polypeptides on the surface of a vaccine vector. Suitably, the antigenic polypeptide and the HMGB1 polypeptide are part of a fusion protein. The two polypeptides may be directly linked via a peptide bond or may be separated by a linker or a section of a third protein into which they are inserted.
Polynucleotides encoding the antigenic polypeptide or HMGB1 polypeptide may be inserted into the vaccine vector and expressed to generate the antigenic polypeptide and the HMGB1 polypeptide. The polynucleotides may be inserted into the chromosome of the vaccine vector or encoded on plasmids or other extrachromosomal DNA. Suitably, polynucleotides encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be expressed independently or are inserted into a vaccine vector polynucleotide that is expressed. Suitably, the vaccine vector polynucleotide encodes a polypeptide expressed on the surface of the vaccine vector such as a transmembrane protein. The polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be inserted into the vaccine vector polynucleotide sequence to allow expression of the antigenic polypeptide and/or the HMGB1 polypeptide on the surface of the vector. For example, the polynucleotide encoding the antigenic polypeptide and the HMGB1 polypeptide may be inserted in frame into a bacterial polynucleotide in a region encoding an external loop region of a transmembrane protein such that the bacterial polynucleotide sequence remains in frame. See Example 1.
Alternatively, the polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide may be inserted into a secreted polypeptide which is displayed or presented on the surface of the vaccine vector through association with a protein, lipid or carbohydrate on the surface of the vaccine vector. Those of skill in the art will appreciate that the polynucleotide encoding the antigenic polypeptide and/or the HMGB1 polypeptide could be inserted in a wide variety of vaccine vector polynucleotides to provide expression and presentation of the antigenic polypeptide and/or the 1-IMGB1 polypeptide to the immune cells of a subject treated with the vaccine vector. In the Examples, several Influenza epitopes including an M2e epitope, a HA
epitope and a NP epitope were expressed from a plasmid for vegetative expression in Bacillus subtilis . The resulting recombinant bacteria express the inserted epitopes as demonstrated by the immune response shown in Figures 1-6.
In the Examples, the vaccine vectors have the antigenic polypeptides (M2c, HA
and NP
polypeptides) and the immunostimulatory polypeptide (either CD154 or HMGB1) encoded on the same polynucleotide and in frame with each other. In alternative embodiments, the immunostimulatory polypeptide and the antigenic polypeptide may be encoded by distinct polynucleotides. Those of skill in the art will appreciate that a variety of methods may be used to obtain expression of the antigenic polypeptide and the HMGB1 polypeptide on the surface of the vaccine vector. Such methods are known to those skilled in the art.
Compositions comprising the vaccine vector and a pharmaceutically acceptable carrier are also provided. A pharmaceutically acceptable carrier is any carrier suitable for in vivo administration. Suitably, the pharamaceutically acceptable carrier is acceptable for oral, nasal or mucosal delivery. The pharmaceutically acceptable carrier may include water, buffered solutions, glucose solutions or bacterial culture fluids. Additional components of the compositions may suitably include excipients such as stabilizers, preservatives, diluents, emulsifiers and lubricants. Examples of pharmaceutically acceptable carriers or diluents include stabilizers such as carbohydrates (e.g., sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein-containing agents such as bovine serum or skimmed milk and buffers (e.g., phosphate buffer). Especially when such stabilizers are added to the compositions, the composition is suitable for freeze-drying or spray-drying.
The vaccine vector in the compositions may not be capable of replication, suitably the vaccine vector is inactivated or killed prior to addition to the composition.
The compositions described herein may be used to enhance an immune response such as an antibody response to the antigenic polypeptide. The compositions containing Influenza polypeptides may also be used to decrease the morbidity associated with subsequent Influenza infection. The compositions may prevent Influenza from causing disease or any associated morbidity in a subject to which the compositions or vaccine vectors described herein were administered. The compositions and vaccine vectors described herein may reduce the severity of subsequent disease by decreasing the length of disease, decreasing the morbidity or mortality associated with the disease or reducing the likelihood of contracting the disease. The morbidity or mortality associated with the disease after administration of the vaccine vectors described herein may be reduced by 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100%
as compared to similar subjects not provided the vaccine vector.
Methods of enhancing immune responses in a subject by administering a vaccine vector are also provided. The vaccine vector may contain a HMGB1 polypeptide capable of stimulating the immune response to the vaccine vector and its associated antigenic polypeptide. The vaccine vector comprising a polypeptide of HMGB1 is administered to a subject in an amount effective to enhance the immune response of the subject to the vaccine and in particular to the antigenic polypeptide. Suitably, the vaccine vector contains a polynucleotide encoding a polypeptide including amino acids 150-183 and 89-109 of the HMGB1 polypeptide (SEQ ID NO:
18) or a homolog thereof In the Examples, a 190 amino acid polypeptide of HMGB1 was used.
Suitably, the polynucleotide encodes a HMGB1 polypeptide from the same species as the subject. Heterologous combinations of HMGB1 polypeptides and subjects (i.e. a human HMGB1 polypeptide for use in a chicken vaccine) may be useful in the methods of the invention because HMGB1 is highly conserved through a wide number of species. The HMGB1 polypeptide may be used to enhance the immune response in the subject to any foreign antigen or antigenic polypeptide present in or on the vaccine vector. One of skill in the art will appreciate that the HMGB1 polypeptide could be used to enhance the immune response to more than one antigenic polypeptide present in a vaccine vector. The polypeptide from HMGB1 stimulates an immune response at least in part by activating dendritic cells and macrophages and thus stimulating production of cytokines such as IL-1, IL-6, IFN-y and TNF-a. In the Examples, a polypeptide of HMGB1 was expressed on the surface of the vaccine vector.
In addition, methods of enhancing an immune response against influenza A and methods of reducing morbidity associated with subsequent Influenza A infection are disclosed. Briefly, the methods comprise administering to a subject a vaccine vector comprising an Influenza A
epitope (an antigenic polypeptide of Influenza) capable of eliciting an immune response in an amount effective to elicit the immune response. The Influenza A epitope may be a M2e polypeptide, an HA polypeptide or a NP polypeptide or another influenza polypeptide as discussed above. The insertion of the antigenic polypeptides into the vaccine vector may be accomplished in a variety of ways known to those of skill in the art, including but not limited to the scarless site-directed mutation system described in International Patent Publication No. WO
2008/036675. The bacterium may also be engineered to express Influenza polypeptides in conjunction with polynucleotides capable of enhancing the immune response as discussed above.
In particular, a polypeptide of CD154 or HMGB1 may be expressed by the vaccine vector to enhance the immune response of the subject to the influenza polypeptides. The Examples demonstrate production of a robust IgA and IgG response to vaccination in chickens. We expect that such a robust response will be protective against or at least reduce the morbidity associated with subsequent infection or challenge with the source of the antigenic polypeptide (Influenza virus in the Examples).
The compositions may be administered by a variety of means including, but not limited to, orally, intranasally, and mucosally. For example, the compositions or vaccine vectors may be delivered by aerosol, by spraying, by addition to food or water, by oral gavage, or via eye drops.
In some embodiments, the compositions are administered by injection such as intradermally, parenterally, subcutaneously, intraperitoneally, intravenously, intracranially, or intramuscularly.
For chickens or other poultry, the compositions may be administered in ovo.
Subjects include, but are not limited to, a vertebrate, suitably a mammal, suitably a human, cows, cats, dogs, pigs, or birds, suitably poultry such as chickens.
Other animal models of infection may also be used. Enhancing an immune response includes, but is not limited to, inducing a therapeutic or prophylactic effect that is mediated by the immune system of the subject. Specifically, enhancing an immune response may include enhanced production of antibodies, such as demonstrated in Figures 1-3, enhanced class switching of antibody heavy chains such as production of IgA as shown in Figure 8, maturation of antigen presenting cells, stimulation of helper T cells, stimulation of cytolytic T cells or induction of T and B cell memory.
The useful dosage to be administered will vary depending on the age, weight and species of the subject, the mode and route of administration and the type of pathogen or disease against which an immune response is sought. The composition may be administered in any dose of vaccine vector sufficient to evoke an immune response. It is envisioned that doses ranging from 103 to 1010 vector copies (i.e. plaque forming or colony forming units), from 104 to 109 vector copies, or from 105 to 107 vector copies are suitable.
The composition may be administered only once or may be administered two or more times to increase the immune response. For example, the composition may be administered two or more times separated by one week, two weeks, or by three weeks, one month, two months, three months, six months or more. The bacteria may be viable prior to administration, but in some embodiments the bacteria may be killed or inactivated prior to administration. In some embodiments, the bacteria may be able to replicate in the subject, while in other embodiments the bacteria may not be capable of replicating in the subject. As shown in the Examples, bacterial vaccine vectors may be inactivated prior to administration using formalin, ethanol, heat or antibiotics. One skilled in the art would appreciate other means of inactivating vaccine vectors could be used as well.
A Bacillus spp. vaccine vector is also provided herein. The Bacillus vaccine vector includes a first polynucleotide sequence encoding an antigenic polypeptide and a second polynucleotide sequence encoding an immunostimulatory polypeptide.
The antigenic polypeptide and the immunostimulatory polypeptide are present on the surface of the Bacillus vaccine vector as described above. The antigenic polypeptide is an Influenza polypeptide as described above and the immunostimulatory polypeptide is a HMGB1 polypeptide as described above or a CD154 polypeptide.
Polynucleotides encoding immunostimulatory polypeptides that are homologous to proteins of the subject and capable of stimulating the immune system to respond to the antigenic polypeptide may also be inserted into a vaccine vector. As described in more detail in the Examples, a vaccine vector may include a CD154 polypeptide that is capable of binding CD40 in the subject and stimulating the subject to respond to the vaccine vector and its associated antigenic polypeptide, similar to 1-1MGB1 described above. The Bacillus vaccine vector may include a HMGB1 polypeptide, a CD154 polypeptide or a combination thereof. As described above, polynucleotides encoding these polypeptides may be inserted into the chromosome of the vaccine vector or maintained extrachromosomally. One of skill in the art will appreciate that these polypeptides can be inserted in a variety of polypeptides of the vaccine vector and expressed in different parts of the vaccine vector or may be secreted.
The polynucleotide encoding an immunostimulatory polypeptide capable of enhancing the immune response to an antigenic polypeptide may also encode the antigenic polypeptide.
The polynucleotide encoding an immunostimulatory polypeptide may be linked to the polynucleotide encoding the antigenic polypeptide, such that in the vaccine vector the immunostimulatory polypeptide and the antigenic polypeptide are encoded by the same polynucleotide. In the Examples, a polynucleotide encoding a polypeptide of CD154, which is capable of binding to CD40, or HMGB1 also encodes an M2e epitope, an HA
epitope and a NP
epitope of Influenza A. See SEQ ID NOs: 19-22. In the Examples, the polynucleotide encoding the Influenza epitopes and the polynucleotide encoding the immunostimulatory polypeptide are both expressed from a plasmid for vegetative cell expression. In some embodiments, the polynucleotides are inserted in the cotB gene or another gene encoding a protein expressed on the surface of spores. Those of skill in the art will appreciate that bacterial polynucleotides encoding other transmembrane proteins may also be used.
As discussed above, a polynucleotide encoding an immunostimulatory polypeptide homologous to a protein of the subject that is capable of enhancing the immune response to the epitope may be included in the vaccine vector. In the Examples, a Bacillus vaccine vector including a polynucleotide encoding either a CD154 polypeptide capable of binding to CD40 or a polypeptide encoding HMGB1 were demonstrated to enhance the immune response to the M2e epitope and to two distinct HA epitopes as measured by increased antibody production in response to vaccination.
Suitably, the CD154 polypeptide is fewer than 50 amino acids long, more suitable fewer than 40, fewer than 30 or fewer than 20 amino acids in length. The polypeptide may be between 10 and 15 amino acids, between 10 and 20 amino acids or between 10 and 25 amino acids in length. The CD154 sequence and CD40 binding region are not highly conserved among the various species. The CD154 sequences of chicken and human are provided in SEQ
ID NO: 11 and SEQ ID NO: 12, respectively.
The CD40 binding regions of CD154 have been determined for a number of species, .. including human, chicken, duck, mouse and cattle and are shown in SEQ ID
NO: 13, SEQ ID
NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, respectively. Although there is variability in the sequences in the CD40 binding region between species, the Examples below indicate that the human CD154 polypeptide was able to enhance the immune response in chickens. Therefore, one may practice the invention using species specific CD154 polypeptides or a heterologous CD 154 polypeptide. In particular, CD154 polypeptides and functional fragments or homologs thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 95% identical, at least 90% identical, at least 85% identical, or at least 80% identical to the CD154 polypeptides of SEQ ID NOs: 11-17.
The Bacillus vaccine vector described herein may be used in the methods of enhancing an immune response and the methods of reducing Influenza morbidity in a subject as described above. The Bacillus vaccine vector may be used to make compositions for administration to subjects such as those described above as well.
Heterologous polynucleotides encoding antigenic polypeptides can be inserted in the bacterial genome at any non-essential site or alternatively may be carried on a plasmid using methods well known in the art. One suitable site for insertion of polynucleotides is within external portions of transmembrane proteins or coupled to sequences which target the hcterologous polynucleotide for secretory pathways. Examples of a suitable transmembrane protein for insertion of polynucleotides are the cotB gene of Bacillus and the lamB gene of Salmonella.
Heterologous polynucleotides include, but are not limited to, polynucleotides encoding antigens selected from pathogenic microorganisms or viruses other than the vaccine vector.
Such polynucleotides may be derived from pathogenic viruses such as influenza (e.g., M2e, hemagglutinin, or neuraminidase), herpesviruses (e.g., the genes encoding the structural proteins of herpesviruses), retroviruses (e.g., the gp160 envelope protein), adenoviruses, paramyxoviruses, coronaviruses and the like. Heterologous polynucleotides can also be obtained from pathogenic bacteria, e.g., genes encoding bacterial proteins such as toxins, and outer membrane proteins. Further, heterologous polynucleotides from parasites, such as Eimeria are attractive candidates for use in a vector vaccine.
Additional immunostimulatory polypeptides involved in triggering the immune system may also be included in the vaccine vectors described herein. The polynucleotides may encode immune system molecules known for their stimulatory effects, such as an interleukin, Tumor Necrosis Factor or an interferon, or another polynucleotide involved in immune-regulation.
The following examples are meant only to be illustrative and are not meant as limitations on the scope of the invention or of the appended claims.
EXAMPLES
Example 1. Construction of HA/NP/M2e/cCD154 and HA/NP/M2e/HMGB1 Bacillus vectors.
Strains and Culture Conditions All plasmids were first maintained in TOP10 E. coli cells (Invitrogen, Carlsbad, CA, USA) unless described otherwise. Bacillus spp. was used for introduction of mutations (Bacillus subtilis, Poultry Health Laboratory strain designated as NP122).
Bacteria carrying plasmid pDGIEF and pHT10 were grown at 37 C.
Luria-Bertani (LB) media was used for routine growth of cells, and SOC media (Invitrogen, Carlsbad, CA, USA) was used for phenotypic expression after electroporation.
When appropriate, the following were added to the media:
Isopropy1-13-D-thiogalactopyranoside (IPTG) at 1m1V1, ampicillin (Amp) at 100 g/ml, spectinomycin (SP) at 100 g/ml, and chloramphenicol (Cm) at 5tig/ml.
Plasmids Plasmids pDGIEF (Bacillus Genetic Stock Center, Columbus, OH) and pHT10 used for the present study were described previously (Zhang et al., Nuc. Acids Research 2006, 34 (9):1-8 and Nguyen et al., Curr. Micro. 2007, 55:89-93). Plasmid pDGIEF served as a template for amplification of the mcaF gene which was used as the counter-selectable marker during Bacillus chromosomal manipulation. Plasmid pHT10 was used to code for and produce the heterologous epitope sequences for Avian Influenza within Bacillus spp. This plasmid contains a CM
resistance gene, is induced by the addition of 1mM IPTG, and is maintained within Bacillus at 37 C.
Production of Heterologous Proteins for Vegetative Cell Expression:
Plasmid pHT10 purchased from MoBioTec/Boca Scientific, Boca Raton, FL (Nguyen et al., 2007) was transformed at the multiple cloning site by addition of a Bacillus subtilis codon optimized insertion sequence. DNA sequencing was done to confirm correct sequence insertion.
The newly modified plasmid was then transformed into Bacillus. Briefly, Bacillus cultures were grown overnight at 37 C in HS media (Spizizcn's medium supplemented with 0.5%
glucose, 50 g/m1 DL-tryptophan, 5014/m1 uracil, 0.02% casein hydrolysate, 0.1% yeast extract, 8p,g/m1 arginine, 0.4 g/m1 histidine, 1mM MgSO4). The overnight culture (1 ml) was used to inoculate 20m1 LS medium (Spizizen's medium supplemented with 0.5% glucose, 5 g/m1 DL-tryptophane, 5 g/m1 uracil, 0.01% casein hydrolysate, 0.1% yeast extract, 1mM
MgSO4, 2.5mM
MgCl2, 0.5mM CaCl2) and incubated with shaking for 3-4 hours at 30 C. To 1 ml of the resulting LS culture 10111 of 0.1M EGTA was added and incubated at room temperature for 5 minutes. Then 1-2 pig plasmid DNA was added, shaken for 2 hours at 37 C, and plated on LB
plates with selective antibiotics. These transformed Bacillus spp. now produce heterologous epitope sequences from AT when induced with 1mM IPTG.
PCR
All primers used for PCR are listed in Table 1. Typical PCR conditions consisted of approximately 0.11ag of purified genomic, plasmid or PCR-generated DNA
(Qiagen, Valencia, CA, USA), lx Pfu polymerase buffer, 5U Pfu polymerase (Stratagene La Jolla, CA, USA), 1mM
dNTPs (GE Healthcare Bio-Sciences Corp., Piscataway, NJ), 1.204 of each primer in a total volume of 50 4. The DNA engine thermal cycler (Bio-Rad, Hercules, CA, USA) was used with the following amplification conditions: 94 C for 2 minutes; 30 cycles of 94 C sec for 30 sec, 58 C for 60 sec, 72 C for 90 sec per 1 kb; and 72 C for 10 minutes for final extension.
Each PCR product was gel purified (Qiagen, Valencia, CA, USA) and either eluted in 254 EB
buffer for preparation of templates used in overlapping extension PCR or in 504 EB buffer, ethanol precipitated and suspended in 54 of ddE120 for electroporation into Bacillus spp.
Table 1: Primer sequences used to generate the vaccine vector Primer Amplified Primer Sequence (SEQ ID NO:) Region mazF for ilfazF gene 5' ctaaaatcttcagatgatcaatcatcctoactgcccgctttccagtogggaaa3' (SEQ ID NO: 31) mazF rev MazF gene 5'tgaacgtgacgaacgaccagatacccectatgcaagggtttat3' (SEQ ID NO: 32) CotB up for Cot B up 5' gaaatgctcgatgctgatga 3' (SEQ ID NO: 33) Cot B up rev Cot B up 5'ggatgattgatcatctgaagattttag3' (SEQ ID NO: 34) Cot B dn for Cot B down 5'aaatctggtcgttcgtcacgttca3' (SEQ ID NO: 35) Cot B dn rev Cot B down 5' ttacgtttccagtgatagtctatcg3' (SEQ ID NO: 36) 5'aaccattetttcaattgtaattgaattttgaatcagtctgcctgatgatgacagttettcataatcattaaaatc for CotB up gcccggatagcacagatcatttgccggatttgctgatgatgaatccatgcctgttctaaccagtgctcttgttc tttgatatgt ggatgattgatcatctgaagattttag3' (SEQ ID NO: 37) 5'ttacaattgaaagaatggttctgteatcatcatcactgctgtcaagaattaatcattttgaaaaaattcaatcat rev CotB down catcagaagttgaaacaccgattagaaattcatcateatggatgacaacatcatatgcaccgacatcatcatca tcagaagttgaaacaccgattagaaataaatctggtcgttcgtcacgtica3' (SEQ ID NO: 38) BS/Al/CD154 BS/AI/CD154 5'ttcaaaatgattaattettgacagcagtgatgatgatgacagaaccattctitcaattgtaattgaattttgaat for CotB up cagtctgcctgatgatgacagttcttcataatcattaaaatcgcccggatagcacagatcatttgccggatttg cggatgattgatcatctgaagattttag3 ' (SEQ ID NO: 39) BS/Al/CD154 BS/AI/CD154 5'caagaattaatcattttgaaaaaattcaatcatcatcagaagttgaaacaccgattagaaattcatcatcactgaaa rev CotB down gaaaaatatgaaaaagatattgcagcatatagagcaaaaggcaaagttgatgcaggcaaaaaagttgttgcaaa agcagaaaaatcaaaaaaaaaatctggtcgttcgtcacgttca3 ' (SEQ ID NO: 40) In Table 1, italicized nucleotides are those which are complementary to either side of the CotB
gene insertion site of Bacillus subtilis.
Electroporation Briefly, cells were inoculated into 10 ml. of LB broth and grown at 37 C
overnight.
Then 1004 of overnight culture was re-inoculated into 10mL fresh LB broth at 37 C for 3-4 hours. Cells were washed five times in ddH20 water and resuspended in 604 of 10% glycerol.
Cells were then pulsed at 2.4-2.45kV for 1-6ms, incubated in 0.5m1 SOC for 2-3 hours at 37 C
and plated on LB media with appropriate antibiotics.
Chromosomal Integration of Heterologous DNA for Spore Coat Expression:
Recombinant Bacillus strains containing stable integrated copies of selected M2e, HA
and NP epitopes were constructed using recently published methods with modification. Briefly, Bacillus strains were transformed with the MazF cassette (Zhang et al., 2006) which generated a strain which was IPTG sensitive and spectomycin resistant. The MazF cassette flanked by approximately 300bp of homologous DNA on each side was introduced into the CotB gene (Isticato et al., 2001) of the Bacillus vector by electroporation followed by growth on media containing spectomycin for positive clones which now contain the MazF cassette which is spectomycin resistant.
After the MazF mutation was confirmed in CotB, this region was replaced by a codon-optimized DNA sequence coding for the antigenic epitopes of Al again flanked by 300 bp of homologous DNA. This was done by creating a PCR product using overlapping and extension PCR to produce the antigenic sequences flanked by approximately 300bp on each side homologous to the Bacillus chromosome (Cox et al., 2007). The PCR product was introduced into the Bacillus again by electroporation and replacement of the MazF
cassette. Transformants were selected on plates containing TPTG, positive clones should now be unresponsive to IPTG
and sensitive to spectomycin. Correct chromosomal sequence insertion was confirmed by DNA
sequencing.
Example 2. Vaccination Study I and 2.
Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=15/treatment group, Exp 1 and n=20/treatment group, Exp 2). All chicks in each treatment group were tagged and numbered.
The chicks were orally infected by gavage with 0.25 ml of saline or 106-108 cfu/ml of the various Bacillus treatments as indicated in Table 2 for study 1 and in Table 3 for study 2.
Table 2. Challenge Dose for each treatment group in Vaccination Study 1.
Treatment Group Challenge Dose Saline only BS/Al/HMGB1 106 cfu/ml BS/Al/HMGB1 108 cfu/ml BS/Al/CD154 106 cfu/ml BS/Al/CD154 108 cfu/ml Table 3. Challenge Dose for each treatment group in Vaccination Study 2.
Treatment Group Challenge Dose BSBB (Bacillus) 106 cfu/ml BS/Al/HMGB1 106 cfu/ml BS/Al/CD154 106 cfu/ml BS/Al/HMGB1 Heat Inactivated 106 cfu/ml BS/AI/HMGB1 Formalin Inactivated 106 cfu/ml BS/Al/HMGB1 Antibiotic Inactivated 106 cfu/ml BS/AI/HMGB1 Ethanol Inactivated 106 cfu/ml In study 2, the bacteria were inactivated in several different ways to assess whether replication was necessary for production of an antibody response directed to the antigenic influenza peptides. Several means of inactivation were used because the means of inactivation could result in destruction of the epitope and result in misinterpretation of the data and supporting a need for replication or viability of the Bacillus vector. The bacteria were inactivated by incubation for 10 minutes in 0.022% formalin (formalin inactivated); incubation for 10 minutes at 70 C (heat inactivated); incubation in 5lig/m1 gentamycin (antibiotic inactivated); or incubation for 10 minutes in 70% ethanol (ethanol inactivated).
Each treatment group was housed in an individual floor pen on fresh pine litter and provided water and feed ad libitum. On days 11 and 21 post-hatch, the birds were given a booster vaccine of the same treatment they received on Day 0. Also on days 21 and 31/32, blood was collected from each of the tagged birds and the serum was removed.
The serum collected from the tagged birds in each treatment group was then used in an antibody capture ELISA to determine specific M2e, HAUA and HALB antibody response. In brief, individual wells of a 96-well plate were coated with 10 g/m1 of the M2e epitope, HAUA
epitope or HALB epitope conjugated to BSA. Antigen adhesion was allowed to proceed overnight at 4 C. Plates were rinsed with PBS + 0.05% Tween 20, blocked with PBS
Superblock (Pierce Chemical Co.) for a minimum of 2 hours and incubated for 2 hours with the serum previously collected from the birds in each of the treatment groups described above. The plates were rinsed with PBS + 0.05% Tween 20 followed by incubation with peroxidase conjugated Goat-anti-Chicken IgY secondary antibody (1:7,500 dilution) obtained from Jackson ImmunoResearch Laboratories (West Grove, PA) for an additional hour. After subsequent rinsing, the plates were developed using a peroxidase substrate kit obtained from Fisher Scientific and absorbances read on a spectrophotometer at 450nm and 405nm.
Pooled serum samples from the groups receiving the vectored vaccine were used as positive controls and pooled serum samples from the unvaccinated groups were used as negative controls on each plate to replace the serum from the treatment groups. The absorbances obtained for the positive control, negative control and experimental samples were used to calculate Sample to Positive control ratios (S/P ratios) using the following calculation:
SIP ratio calculation: sample mean ¨ negative control mean positive control mean ¨ negative control mean The calculated S/P ratios for each study are shown in Figures 1-6. Figures 1-3 show the total antibody titers for M2e, HALB and HAUA for study 1, respectively, at days 21 and 31 post-hatch. The results demonstrate that robust immune responses to each of these antigens were generated after oral administration with a Bacillus expressing each of the epitopes with either CD154 of HMGB1 as the immunostimulatory peptide. Figures 4-6 show the total antibody titers for M2e, HALB and HAUA for study 2, respectively, at days 21 and 32 post-hatch. The results demonstrate that robust immune responses to each of the epitopes were generated after oral administration of a live Bacillus expressing the epitope and an immunostimulatory peptide.
Figures 4-6 also demonstrate that similar levels of specific antibodies were generated when the vector (the Bacillus) was inactivated prior to administration.
Example 3. Vaccination Study 3 Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=20/treatment group). All chicks in each treatment group were tagged and numbered. The chicks were orally infected by gavage with 0.25 ml of saline or 105-108 cfu/m1 of the Bacillus vector (BSBB), the Bacillus vector expressing the avian influenza epitopes and HMGB1 (BS/AI/HMGB1), or various amounts of the vector after formalin inactivation (as described above). On day 10 post-hatch, the birds were given a booster vaccine of the same treatment they received on Day 0. Also on days 21 and 32, blood was collected from each of the tagged birds and the serum was removed.
The serum IgG
M2e specific antibody levels were determined using the method described above with a peroxidase labeled anti-chicken TgG specific secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). The results in Figure 7 show that the formalin inactivated bacteria were able to stimulate production of M2e specific IgG antibodies as well as live bacteria. This result was surprising because it was generally believed that only live bacteria could stimulate a robust immune response after oral administration.
Example 4. Vaccination Study 4 Day-of-hatch (day 0) chicks were obtained from a local commercial hatchery and randomly distributed into treatment groups (n=20-35/treatment group). All chicks in each treatment group were tagged and numbered. The chicks were orally infected by gavage or injected sub-cutaneously with 0.25 ml of 106 cfu/ml of the Bacillus vector (BSBB), the Bacillus vector expressing the avian influenza epitopes and HMGB1 (BSAI), or the BSAI
vector after formalin inactivation (as described above) or after formalin inactivation followed by lyophilization (reconstituted with saline immediately prior to administration). On day 10 post-hatch, some of the birds were given a booster vaccine of the same treatment they received on .. Day 0. On days 11, 14 and 21, blood was collected from each of the tagged birds and the serum was removed. The serum IgA and IgG M2e specific antibody levels were determined using the method described above with a perioxidase labeled anti-chicken IgA (GenTex) or a perioxidase labeled anti-chicken TgG specific secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). The results in Figure 8 show that the formalin inactivated bacteria were able to stimulate production of M2e specific IgA antibodies about as well as live bacteria when given orally. In contrast when given sub-cutaneously the inactivated BSAI vector was not as efficient at stimulating an IgA antibody response and the lyophilized bacteria did not stimulate an IgA
response. The results in Figure 9 show that each of the BSAI administration protocols supported robust IgG formation.
Claims (66)
1. A vaccine vector comprising an antigenic polypeptide and an IIIVIGB1 polypeptide each comprised within a transmembrane protein, wherein at least a portion of the antigenic polypeptide and at least a portion of the IIIVIGB1 polypeptide are present on the surface of the vaccine vector.
2. The vaccine vector of claim 1, wherein the antigenic polypeptide is an Influenza specific polypeptide.
3. The vaccine vector of claim 2, wherein the antigenic polypeptide is an M2e, HA
or NP Influenza polypeptide.
or NP Influenza polypeptide.
4. The vaccine vector of claim 3, wherein the antigenic polypeptide is SEQ
ID
NO:1, SEQ ID NO:2, SEQ NO:3, SEQ NO:4, SEQ NO:5, SEQ ID NO:6, SEQ NO:
7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, an immunogenic fragment of SEQ
ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID
NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID NO:5, an immunogenic fragment of SEQ ID NO:6, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
ID
NO:1, SEQ ID NO:2, SEQ NO:3, SEQ NO:4, SEQ NO:5, SEQ ID NO:6, SEQ NO:
7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, an immunogenic fragment of SEQ
ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID
NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID NO:5, an immunogenic fragment of SEQ ID NO:6, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
5. The vaccine vector of any one of claims 1-4, wherein the IIIVIGB1 polypeptide is:
SEQ ID NO: 18, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ
ID
NO: 29, SEQ ID NO: 30; a functional fragment of any one of SEQ ID NOS: 18 or 25-30 that retains the inflammatory activity of the IIIVIGB1 polypeptide of any one of SEQ ID NOS: 18 or 25-30; or a homolog that is at least 95% identical to any one of the HMGB1 polypeptides of SEQ
ID NOs:18 or 25-30 and retains the inflammatory activity of the IIIVIGB1 polypeptides of SEQ
ID NOs:18 or 25-30.
SEQ ID NO: 18, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ
ID
NO: 29, SEQ ID NO: 30; a functional fragment of any one of SEQ ID NOS: 18 or 25-30 that retains the inflammatory activity of the IIIVIGB1 polypeptide of any one of SEQ ID NOS: 18 or 25-30; or a homolog that is at least 95% identical to any one of the HMGB1 polypeptides of SEQ
ID NOs:18 or 25-30 and retains the inflammatory activity of the IIIVIGB1 polypeptides of SEQ
ID NOs:18 or 25-30.
6. The vaccine vector of any one of claims 1-5, wherein the vaccine vector is a bacterium, a virus, a liposome or a yeast.
Date Recue/Date Received 2021-05-03
Date Recue/Date Received 2021-05-03
7. The vaccine vector of claim 6, wherein: the bacterium is Bacillus spp, Salmonella enteritidis, Shigella, E. coli, Yersinia, Bordetella, Lactococcus, Streptococcus, Vibrio cholera or Listeria; and, the virus is adenovirus, poxvirus, herpesvirus, alphavirus or adeno-associated virus.
8. The vaccine vector of any one of claims 1-7, wherein the antigenic polypeptide and/or the IIIVIGB1 polypeptide is within an external loop of the transmembrane protein.
9. The vaccine vector of any one of claims 1-8, wherein the transmembrane protein is cotB.
10. The vaccine vector of any one of claims 1-9, wherein the antigenic polypeptide and the HMGB1 polypeptide are part of a fusion protein.
11. A composition comprising the vaccine vector of any one of claims 1-10 and a pharmaceutically acceptable carrier.
12. The composition of claim 11, wherein the pharmaceutically acceptable carrier is acceptable for oral or nasal administration.
13. The composition of claim 11 or 12, wherein the vaccine vector is not capable of replication, is inactivated or is killed.
14. Use of the vaccine vector of any one of claims 1-10 or the composition of any one of claims 1 1- 13 in the manufacture of a medicament to enhance the immune response of a subject to the antigenic polypeptide.
15. The use of claim 14, wherein the vaccine vector is formulated to be administered orally or intranasally.
16. The use of claim 15, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
17. A Bacillus spp. vaccine vector comprising a first polynucleotide sequence encoding an antigenic polypeptide present on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide, wherein the antigenic Date Recue/Date Received 2021-05-03 polypeptide and the immunostimulatory polypeptide are present on the surface of the vaccine vector, wherein the antigenic polypeptide is an Influenza polypeptide and wherein the immunostimulatory polypeptide is a HIVIGB1 polypeptide, and wherein the first polynucleotide and the second polynucleotide are inserted within a third polynucleotide sequence encoding an external portion of a transmembrane protein.
18. The vaccine vector of claim 17, wherein the transmembrane protein is cotB.
19. The vaccine vector of any one of claims 17-18, wherein the antigenic polypeptide is an Influenza M2e polypeptide, an Influenza HA polypeptide, or an Influenza NP polypeptide.
20. The vaccine vector of claim 19, wherein the antigenic polypeptide is SEQ ID
NO:1, SEQ ID NO:2, SEQ NO:3, SEQ NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, an immunogenic fragment of SEQ
ID
NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ
ID NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID
NO:5, an immunogenic fragment of SEQ ID NO:6, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
NO:1, SEQ ID NO:2, SEQ NO:3, SEQ NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, an immunogenic fragment of SEQ
ID
NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ
ID NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID
NO:5, an immunogenic fragment of SEQ ID NO:6, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
21. The vaccine vector of any one of claims 17-20, wherein the HMGB1 polypeptide is SEQ ID NO: 18, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID
NO: 29, SEQ ID NO: 30, a functional fragment of any one of SEQ ID NOS: 18 or 25-30 that retains the inflammatory activity of the HIVIGB1 polypeptide of any one of SEQ
ID NOS: 18 or 25-30, or a homolog that is at least 95% identical to any one of the HIVIGB1 polypeptides of SEQ
ID Nos:18 or 25-30 and retains the inflammatory activity of the HIVIGB1 polypeptides of SEQ
ID Nos:18 or 25-30.
NO: 29, SEQ ID NO: 30, a functional fragment of any one of SEQ ID NOS: 18 or 25-30 that retains the inflammatory activity of the HIVIGB1 polypeptide of any one of SEQ
ID NOS: 18 or 25-30, or a homolog that is at least 95% identical to any one of the HIVIGB1 polypeptides of SEQ
ID Nos:18 or 25-30 and retains the inflammatory activity of the HIVIGB1 polypeptides of SEQ
ID Nos:18 or 25-30.
22. Use of the Bacillus spp. vaccine vector of any one of claims 17-21 in the manufacture of a medicament to enhance the immune response of a subject to the antigenic polypeptide.
Date Recue/Date Received 2021-05-03
Date Recue/Date Received 2021-05-03
23. The use of claim 22, wherein the vaccine vector is formulated to be administered orally or intranasally.
24. The use of claim 23, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
25. The use of any one of claims 22-24, wherein the vaccine vector is not capable of replication in the subject or is inactivated or killed.
26. Use of the vaccine vector of any one of claims 1-10 or 17-21 or the composition of any one of claims 1 1- 13 in the manufacture of a medicament to reduce Influenza A related morbidity in a subject.
27. Use of the vaccine vector of any one of claims 1-10 or the composition of any one of claims 11-13 for the enhancement of the immune response of a subject to the antigenic polypeptide.
28. The use of claim 27, wherein the vaccine vector is formulated to be administered orally or intranasally.
29. The use of claim 28, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
30. Use of the Bacillus spp. vaccine vector of any one of claims 17-21 for the enhancement of the immune response of a subject to the antigenic polypeptide.
31. The use of claim 30, wherein the vaccine vector is formulated to be administered orally or intranasally.
32. The use of claim 31, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
33. The use of any one of claims 30-32, wherein the vaccine vector is not capable of replication in the subject or is inactivated or killed.
Date Recue/Date Received 2021-05-03
Date Recue/Date Received 2021-05-03
34. A vaccine vector comprising an antigenic polypeptide and an HIVIGB1 polypeptide each comprised within a transmembrane protein, wherein at least a portion of the antigenic polypeptide and at least a portion of the HIVIGB1 polypeptide are present on the surface of the vaccine vector, and wherein the HIVIGB1 polypeptide is SEQ ID NO: 18, a functional fragment of SEQ ID NO: 18 that retains the inflammatory activity of the HIVIGB1 polypeptide of SEQ ID NO: 18, or a homolog that is at least 95% identical to the HIVIGB1 polypeptide of SEQ
ID NO:18 and retains the inflammatory activity of the HIVIGB1 polypeptide of SEQ ID NO:18.
ID NO:18 and retains the inflammatory activity of the HIVIGB1 polypeptide of SEQ ID NO:18.
35. The vaccine vector of claim 34, wherein the antigenic polypeptide is an Influenza specific polypeptide.
36. The vaccine vector of claim 35, wherein the antigenic polypeptide is an M2e, HA
or NP Influenza polypeptide.
or NP Influenza polypeptide.
37. The vaccine vector of claim 36, wherein the antigenic polypeptide is SEQ ID
NO:1, SEQ NO:2, SEQ NO:3, SEQ NO:4, SEQ NO:5, SEQ ID NO:6, SEQ NO:
7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, an immunogenic fragment of SEQ
ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID
NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID NO:5, an immunogenic fragment of SEQ 1113 NO:6, an immunogenic fragment of SEQ ID NO:
7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
NO:1, SEQ NO:2, SEQ NO:3, SEQ NO:4, SEQ NO:5, SEQ ID NO:6, SEQ NO:
7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, an immunogenic fragment of SEQ
ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID
NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID NO:5, an immunogenic fragment of SEQ 1113 NO:6, an immunogenic fragment of SEQ ID NO:
7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
38. The vaccine vector of any one of claims 34-37, wherein the vaccine vector is a bacterium, a virus, a liposome or a yeast.
39. The vaccine vector of claim 38, wherein: the bacterium is Bacillus spp, Salmonella enteritidis, Shigella, E. coli, Yersinia, Bordetella, Lactococcus, Streptococcus, Vibrio cholera or Listeria; and, the virus is adenovirus, poxvirus, herpesvirus, alphavirus or adeno-associated virus.
40. The vaccine vector of any one of claims 34-39, wherein the antigenic polypeptide and/or the HIVIGB1 polypeptide is within an external loop of the transmembrane protein.
Date Recue/Date Received 2021-05-03
Date Recue/Date Received 2021-05-03
41. The vaccine vector of any one of claims 34-40, wherein the transmembrane protein is cotB.
42. The vaccine vector of any one of claims 34-41, wherein the antigenic polypeptide and the HMGB1 polypeptide are part of a fusion protein.
43. A composition comprising the vaccine vector of any one of claims 34-42 and a pharmaceutically acceptable carrier.
44. The composition of claim 43, wherein the pharmaceutically acceptable carrier is acceptable for oral or nasal administration.
45. The composition of claim 43 or 44, wherein the vaccine vector is not capable of replication, is inactivated or is killed.
46. Use of the vaccine vector of any one of claims 34-42 or the composition of any one of claims 43-45 in the manufacture of a medicament to enhance the immune response of a subject to the antigenic polypeptide.
47. The use of claim 46, wherein the vaccine vector is formulated to be administered orally or intranasally.
48. The use of claim 47, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
49. Use of the vaccine vector of any one of claims 34-42 or the composition of any one of claims 43-45 for the enhancement of the immune response of a subject to the antigenic polypeptide.
50. The use of claim 49, wherein the vaccine vector is formulated to be administered orally or intranasally.
51. The use of claim 50, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
Date Recue/Date Received 2021-05-03
Date Recue/Date Received 2021-05-03
52. A Bacillus spp. vaccine vector comprising a first polynucleotide sequence encoding an antigenic polypeptide present on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide, wherein the antigenic polypeptide and the immunostimulatory polypeptide are present on the surface of the vaccine vector, wherein the antigenic polypeptide is an Influenza polypeptide and wherein the immunostimulatory polypeptide is a HIVIGB1 polypeptide, and wherein the first polynucleotide and the second polynucleotide are inserted within a third polynucleotide sequence encoding an external portion of a transmembrane protein, and wherein the HIVIGB1 polypeptide is SEQ ID
NO: 18, a functional fragment of SEQ ID NO: 18 that retains the inflammatory activity of the HIVIGB1 polypeptide of SEQ ID NO: 18, or a homolog that is at least 95%
identical to the HIVIGB1 polypeptide of SEQ ID NO:18 and retains the inflammatory activity of the HIVIGB1 polypeptide of SEQ ID NO:18.
NO: 18, a functional fragment of SEQ ID NO: 18 that retains the inflammatory activity of the HIVIGB1 polypeptide of SEQ ID NO: 18, or a homolog that is at least 95%
identical to the HIVIGB1 polypeptide of SEQ ID NO:18 and retains the inflammatory activity of the HIVIGB1 polypeptide of SEQ ID NO:18.
53. The vaccine vector of claim 52, wherein the transmembrane protein is cotB.
54. The vaccine vector of any one of claims 52-53, wherein the antigenic polypeptide is an Influenza M2e polypeptide, an Influenza HA polypeptide, or an Influenza NP polypeptide.
55. The vaccine vector of claim 54, wherein the antigenic polypeptide is SEQ ID
NO:1, SEQ NO:2, SEQ NO:3, SEQ NO:4, SEQ NO:5, SEQ ID NO:6, SEQID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, an immunogenic fragment of SEQ
ID
NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ
ID NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID
NO:5, an immunogenic fragment of SEQ ID NO:6, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
NO:1, SEQ NO:2, SEQ NO:3, SEQ NO:4, SEQ NO:5, SEQ ID NO:6, SEQID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, an immunogenic fragment of SEQ
ID
NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ
ID NO:3, an immunogenic fragment of SEQ ID NO:4, an immunogenic fragment of SEQ ID
NO:5, an immunogenic fragment of SEQ ID NO:6, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9 or an immunogenic fragment of SEQ ID NO: 10.
56. Use of the Bacillus spp. vaccine vector of any one of claims 52-55 in the manufacture of a medicament to enhance the immune response of a subject to the antigenic polypeptide.
57. The use of claim 56, wherein the vaccine vector is formulated to be administered orally or intranasally.
Date Recue/Date Received 2021-05-03
Date Recue/Date Received 2021-05-03
58. The use of claim 57, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
59. The use of any one of claims 56-58, wherein the vaccine vector is not capable of replication in the subject or is inactivated or killed.
60. Use of the vaccine vector of any one of claims 34-42 or 52-55 or the composition of any one of claims 43-45 in the manufacture of a medicament to reduce Influenza A related morbidity in a subject.
61. Use of the Bacillus spp. vaccine vector of any one of claims 52-55 for the enhancement of the immune response of a subject to the antigenic polypeptide.
62. The use of claim 61, wherein the vaccine vector is formulated to be administered orally or intranasally.
63. The use of claim 62, wherein the immune response is an IgA antibody response to the antigenic polypeptide.
64. The use of any one of claims 61-63, wherein the vaccine vector is not capable of replication in the subject or is inactivated or is killed.
65. Use of the vaccine vector of any one of claims 1-10 or 17-21 or the composition of any one of claims 1 1- 13 for the reduction of Influenza A related morbidity in a subject.
66. Use of the vaccine vector of any one of claims 34-42 or 52-55 or the composition of any one of claims 43-45 for the reduction of Influenza A related morbidity in a subject.
Date Recue/Date Received 2021-05-03
Date Recue/Date Received 2021-05-03
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29709810P | 2010-01-21 | 2010-01-21 | |
US61/297,098 | 2010-01-21 | ||
PCT/US2011/022062 WO2011091255A1 (en) | 2010-01-21 | 2011-01-21 | Vaccine vectors and methods of enhancing immune responses |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2787661A1 CA2787661A1 (en) | 2011-07-28 |
CA2787661C true CA2787661C (en) | 2021-10-12 |
Family
ID=44307229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2787661A Active CA2787661C (en) | 2010-01-21 | 2011-01-21 | Vaccine vectors and methods of enhancing immune responses |
Country Status (21)
Country | Link |
---|---|
US (2) | US8956618B2 (en) |
EP (1) | EP2525817B8 (en) |
JP (3) | JP6242050B2 (en) |
KR (1) | KR101638661B1 (en) |
CN (1) | CN102811734B (en) |
AU (1) | AU2011207331C1 (en) |
CA (1) | CA2787661C (en) |
CL (1) | CL2012002016A1 (en) |
CO (1) | CO6561819A2 (en) |
DK (1) | DK2525817T3 (en) |
EA (1) | EA023058B1 (en) |
ES (1) | ES2643646T3 (en) |
HU (1) | HUE037157T2 (en) |
MX (1) | MX341775B (en) |
NO (1) | NO2525817T3 (en) |
NZ (1) | NZ601609A (en) |
PL (1) | PL2525817T3 (en) |
PT (1) | PT2525817T (en) |
UA (1) | UA110024C2 (en) |
WO (1) | WO2011091255A1 (en) |
ZA (1) | ZA201205824B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2214701T3 (en) * | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
UA110024C2 (en) | 2010-01-21 | 2015-11-10 | VACCINE VECTOR AND METHOD OF IMMUNE IMPROVEMENT | |
KR102007132B1 (en) * | 2010-06-09 | 2019-08-05 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | Vaccine and methods to reduce campylobacter infection |
WO2012072788A1 (en) | 2010-12-02 | 2012-06-07 | Mab-Factory Gmbh | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
NZ711019A (en) * | 2013-02-14 | 2019-07-26 | Univ Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
EP2968423A4 (en) | 2013-03-15 | 2016-11-09 | Univ Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
CN105399808B (en) * | 2015-11-23 | 2019-05-10 | 青岛农业大学 | A kind of flat Rockfish Immune-enhancing effect albumen HMGB1 gene of Xu Shi and coding albumen and application |
BR112018072592A2 (en) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | yeast vaccine vector that includes immunostimulating and antigenic polypeptides, and methods of using them |
US11744875B2 (en) | 2019-07-12 | 2023-09-05 | Op-T Llc | Peptides and methods for treating disease |
US12048734B2 (en) | 2020-04-17 | 2024-07-30 | Op-T Llc | Bioactive peptides and methods of use thereof |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100240182B1 (en) | 1991-03-05 | 2000-01-15 | 레슬리 제인 에드워즈 | Expression of recombinant proteins in attenuated bacteria |
US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
DK0822199T3 (en) | 1991-10-25 | 2004-12-27 | Amgen Inc | N-terminally monopegylated polypeptides and methods for their preparation |
US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
DE69322092T2 (en) | 1992-09-04 | 1999-07-15 | University Of Saskatchewan, Saskatoon | NEW BACTERIAL VACCINES USING VACCINE STRAINS FROM PATHOGENIC BACTERIA |
AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
JP3657271B2 (en) | 1995-03-01 | 2005-06-08 | イミュネックス・コーポレーション | Composition for the treatment of mammals infected with pathogenic or opportunistic infectious organisms |
AU693713B2 (en) | 1995-06-07 | 1998-07-02 | Immunex Corporation | CD40L mutein |
US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US6306387B1 (en) | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
CA2313805A1 (en) | 1997-12-19 | 1999-07-01 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
GB9806449D0 (en) | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
IT1299583B1 (en) | 1998-05-19 | 2000-03-16 | Vander Way Limited | USE OF HMG-I PROTEIN FOR THE PREPARATION OF MEDICATIONS WITH CYTOTOXIC ACTIVITY |
EP1108034B1 (en) | 1998-09-04 | 2008-08-06 | Emergent Product Development UK Limited | Attenuated salmonella spi2 mutants as antigen carriers |
US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
WO2001026608A2 (en) | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
MXPA00012796A (en) | 1999-12-28 | 2002-05-23 | Akzo Nobel Nv | Salmonella vaccine. |
EP1255560B1 (en) | 2000-02-02 | 2008-10-29 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE | Cd40 ligand adjuvant for respiratory syncytial virus vaccine |
ATE300949T1 (en) | 2000-03-17 | 2005-08-15 | Pharmacia & Upjohn Co Llc | SSA INACTIVATED SALMONELLA VACCINES |
GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
WO2002000232A2 (en) * | 2000-06-26 | 2002-01-03 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
SK15422003A3 (en) | 2001-05-15 | 2005-01-03 | Research Institute North Shore-Long Island Jewish | Use of HMG fragment as anti-inflammatory agents |
EP2687593A1 (en) | 2001-05-15 | 2014-01-22 | Ortho-McNeil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
ITMI20011986A1 (en) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | METHOD AND COMPOSITION FOR THE ACTIVATION OF CELLS PRESENTING THE ANTIGEN |
CA2470640A1 (en) | 2001-12-19 | 2003-06-26 | Alcedo Biotech Gmbh | Use of hmgb proteins and nucleic acids that code therefor |
US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
EP1499191B1 (en) | 2002-04-15 | 2012-05-09 | Washington University in St. Louis | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
US20060121047A1 (en) | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
NZ540067A (en) | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
US20060014248A1 (en) | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
US20050181994A1 (en) | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
EP1673389A2 (en) | 2003-10-10 | 2006-06-28 | Xencor Inc. | Novel variants of cd40l protein |
US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
WO2005058950A2 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
JP2008508855A (en) | 2004-04-27 | 2008-03-27 | インターツェル・アクチェンゲゼルシャフト | TD antigen |
WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
EP1768698A4 (en) * | 2004-06-17 | 2009-01-28 | Medimmune Inc | Immunogenic compositions comprising hmgb1 polypeptides |
WO2006012373A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
CN101080487B (en) | 2004-10-07 | 2012-11-14 | 阿戈斯治疗公司 | Mature dendritic cell compositions and methods for culturing same |
GB0423681D0 (en) | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
CA2593746A1 (en) | 2004-12-21 | 2006-06-29 | Vaxinnate Corporation | Compositions of influenza viral proteins and methods of use thereof |
WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
US20060286074A1 (en) | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
EP1909834A2 (en) | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
JP2009511452A (en) | 2005-10-07 | 2009-03-19 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ | Combination of immunostimulants for the prevention and treatment of hepatitis C |
EP1951862B1 (en) | 2005-11-07 | 2013-07-24 | MicroVAX, LLC | Cd40 ligand fusion protein vaccine |
WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
WO2007130725A2 (en) | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
US8802419B2 (en) | 2006-03-02 | 2014-08-12 | University Of Massachusetts | Modified pathogens for use as vaccines |
WO2008094197A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
US8564612B2 (en) * | 2006-08-04 | 2013-10-22 | Apple Inc. | Deep pixel pipeline |
CN104278014A (en) * | 2006-08-09 | 2015-01-14 | 米迪缪尼有限公司 | Influenza hemagglutinin and neuraminidase variants |
CN101522210B (en) * | 2006-09-18 | 2017-03-22 | 阿肯色大学评议会 | Compositions and methods for enhancing immune responses |
WO2008109825A2 (en) | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
AU2008275513A1 (en) * | 2007-05-02 | 2009-01-15 | Emory University | Enhancement of glycoprotein incorporation into virus-like particles |
NZ585776A (en) | 2007-10-30 | 2012-07-27 | Univ Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
PL2214701T3 (en) | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
UA110024C2 (en) | 2010-01-21 | 2015-11-10 | VACCINE VECTOR AND METHOD OF IMMUNE IMPROVEMENT | |
KR102007132B1 (en) | 2010-06-09 | 2019-08-05 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | Vaccine and methods to reduce campylobacter infection |
MX2014005754A (en) | 2011-11-11 | 2015-02-10 | Nutrition Physiology Company Llc | Lactic acid bacteria and their use as dietary supplementals for poultry. |
-
2011
- 2011-01-21 UA UAA201210026A patent/UA110024C2/en unknown
- 2011-01-21 EA EA201290675A patent/EA023058B1/en not_active IP Right Cessation
- 2011-01-21 US US13/574,504 patent/US8956618B2/en active Active
- 2011-01-21 ES ES11735230.2T patent/ES2643646T3/en active Active
- 2011-01-21 AU AU2011207331A patent/AU2011207331C1/en active Active
- 2011-01-21 KR KR1020127021697A patent/KR101638661B1/en active IP Right Grant
- 2011-01-21 CA CA2787661A patent/CA2787661C/en active Active
- 2011-01-21 MX MX2012008506A patent/MX341775B/en active IP Right Grant
- 2011-01-21 HU HUE11735230A patent/HUE037157T2/en unknown
- 2011-01-21 WO PCT/US2011/022062 patent/WO2011091255A1/en active Application Filing
- 2011-01-21 JP JP2012550153A patent/JP6242050B2/en active Active
- 2011-01-21 DK DK11735230.2T patent/DK2525817T3/en active
- 2011-01-21 EP EP11735230.2A patent/EP2525817B8/en active Active
- 2011-01-21 NZ NZ601609A patent/NZ601609A/en unknown
- 2011-01-21 CN CN201180006369.8A patent/CN102811734B/en active Active
- 2011-01-21 PL PL11735230T patent/PL2525817T3/en unknown
- 2011-01-21 PT PT117352302T patent/PT2525817T/en unknown
- 2011-01-21 NO NO11735230A patent/NO2525817T3/no unknown
-
2012
- 2012-07-19 CO CO12122137A patent/CO6561819A2/en not_active Application Discontinuation
- 2012-07-20 CL CL2012002016A patent/CL2012002016A1/en unknown
- 2012-08-02 ZA ZA2012/05824A patent/ZA201205824B/en unknown
-
2015
- 2015-02-16 US US14/623,105 patent/US9913893B2/en active Active
-
2016
- 2016-03-08 JP JP2016044306A patent/JP2016117757A/en active Pending
-
2017
- 2017-12-05 JP JP2017233454A patent/JP6687585B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2787661C (en) | Vaccine vectors and methods of enhancing immune responses | |
US11013792B2 (en) | Compositions and methods of enhancing immune responses to enteric pathogens | |
JP6874031B2 (en) | Compositions and Methods to Enhance the Immune Response to Eimeria or Limit Eimeria Infections | |
JP5480812B2 (en) | Compositions and methods for enhancing immune responses against Eimeria | |
JP5746333B2 (en) | Vaccines and methods for reducing Campylobacter infection | |
KR101525180B1 (en) | Cell Surface Expression Vector for Influenza Virus Antigen and Microorganisms Transformed Thereby | |
BR112012018027B1 (en) | Vaccine vectors and methods of improving immune responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20151223 |